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A B S T R A C T
Background
Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity in multiple
sclerosis (MS) patients.
This is an update of the Cochrane review “Mitoxantrone for multiple sclerosis” (published on Cochrane Database of Systematic Reviews
2013, Issue 5).
Objectives
The main objective was to assess the efficacy and safety of MX compared to a control group in relapsing-remitting (RRMS), progressive
relapsing (PRMS) and secondary progressive (SPMS) MS participants.
Search methods
We searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Specialised Register (23 May
2013). We also undertook handsearching and contacted trialists and pharmaceutical companies.
Selection criteria
Randomised, double-blinded, controlled trials (RCTs) comparing the administration of MX versus placebo or MX plus steroids
treatment versus placebo plus steroids treatment were included.
Data collection and analysis
The review authors independently selected articles for inclusion. They independently extracted clinical, safety and magnetic resonance
imaging (MRI) data, resolving disagreements by discussion. Risk of bias was evaluated to assess the quality of the studies. Treatment
effect was measured using odds ratios (OR) with 95% confidence intervals (CI) for the binary outcomes and mean differences (MD)
with 95% CI for the continuous outcomes. If heterogeneity was absent, a fixed-effect model was used.
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Main results
Three trials were selected and 221 participants were included in the analyses. MX reduced the progression of disability at two years
follow-up (proportion of participants with six months confirmed progression of disability (OR 0.30, 95% CI 0.09 to 0.99 and MD -
0.36, 95% CI- 0.70 to -0.02; P = 0.04). Significant results were found regarding the reduction in annualised relapse rate (MD -0.85,
95% CI -1.47 to -0.23; P = 0.007), the proportion of patients free from relapses at one year (OR 7.13, 95% CI 2.06 to 24.61; P =
0.002) and two years (OR 2.82, 95% CI 1.54 to 5.19; P = 0.0008), and the number of patients with active MRI lesions at six months
or one year only (OR 0.24, 95% CI 0.10 to 0.57; P = 0.001).
Side effects reported in the trials (amenorrhoea, nausea and vomiting, alopecia and urinary tract infections) were more frequent in
treated patients than in controls, while no major adverse events have been reported. These results should be considered with caution
because of the limited number of included subjects the heterogeneous characteristics of included trials in term of drug dosage, inclusion
criteria and quality of included trials. Moreover, it was not possible to estimate the long-term efficacy and safety of MX.
Authors’ conclusions
MX shows a significant but partial efficacy in reducing the risk of MS progression and the frequency of relapses in patients affected by
worsening RRMS, PRMS and SPMS in the short-term follow-up (two years). Nomajor neoplastic events or symptomatic cardiotoxicity
related to MX have been reported; however studies with longer follow-up (not included in this review) have raised concerns about the
risk of systolic disfunction and therapy-related acute leukaemias, occurring in about 12% and 0.8% of MX-treated patients respectively.
MX should be limited to treating patients with worsening RRMS and SPMS and with evidence of persistent inflammatory activity
after a careful assessment of the individual patients’ risk and benefit profiles. Assessment should also consider the present availability of
alternative therapies with less severe adverse events.
P L A I N L A N G U A G E S U M M A R Y
The use of the immunosuppressive drug mitoxantrone (MX) in people with multiple sclerosis (MS)
This is an update of the Cochrane review “Mitoxantrone for multiple sclerosis” (published on Cochrane Database of Systematic Reviews
2013, Issue 5).
MX is considered an immune-mediated chronic disorder of the central nervous system (CNS), characterized by multiple areas of
inflammation and demyelination. Several drugs such as steroids as well as immunomodulant and immunosuppressive agents have
been used to treat the disease course. Among them, MX, an immunosuppressive agent widely used for treatment of breast cancer and
leukaemia, has been tested in MS individuals. Two hundred seventy-five articles were identified by the search strategy up to May 2013.
Three trials contributed to this review, comprising a total of 221 participants. Data show that MX was moderately effective in reducing
the risk of MS progression and the frequency of relapses in short-term follow-up (up to two years) of patients affected by worsening
relapsing-remitting MS (RRMS), progressive relapsing MS (PRMS) and secondary progressive MS (SPMS). However, caution must
be exercised when interpreting these results because of the heterogeneous characteristics and quality of the included trials, which are
different in terms of treatment schedules and types of enrolled patients.
The most frequent adverse effects were nausea and vomiting, alopecia, urinary tract infections and transitory leucopenia; 35% of MX-
treated female participants developed transitory amenorrhoea, and almost 15% developed a persistent amenorrhoea which was still
present at the end of the follow-up period. Data from studies with longer follow-up and out of included trials have raised concerns
about cardiotoxicity and acute leukaemias, occurring in about 12% and 0.8% of MX-treated patients respectively.
For these reasons, MX treatment should be limited to patients with worsening RRMS and SPMS after a careful assessment of the
individual patients’ risk and benefit profiles, also considering the present availability of alternative therapies with less severe adverse
events. Moreover, MX-treated patients need to be followed-up after the end of treatment to control the risk of serious adverse events.
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B A C K G R O U N D
Description of the condition
Multiple sclerosis (MS) is an immune-mediated chronic disorder
of the central nervous system (CNS) characterized by multiple
areas of inflammation and demyelination. Neuropathological ev-
idence indicates that activated T cells enter the CNS across small
veins and produce an immune cascade effect, causing localized
areas of myelin, oligodendrocyte and axonal loss. The resulting
lesions (called plaques) accumulate over time and determine the
progressive increase of disease burden.
MS is among the commonest causes of neurological disability in
young people and it has an annual incidence ranging from 2 to
10 cases/100,000 persons/year. A north-south gradient was found,
with lower incidence being closer to the equator (Compston
1998). Its clinical manifestations typically occur between 20 and
40 years of age with symptoms and signs involving different CNS
regions (optic nerve, brainstem, cerebellum, cerebral hemispheres,
spinal cord) (Compston 1998).
There are different clinical phenotypes of MS. About 85% of MS
patients have an initial relapsing-remitting (RR) form, character-
ized by acute attacks or relapses with the appearance of neurologi-
cal deficits followed by a partial or complete remission. By defini-
tion, an attack should last for more than 24 hours. Between attacks
patients are clinically stable. Among RRMS patients, 20% have a
milder form of the disease, defined as benign MS. These patients
are fully functional after 15 years from disease onset. After a RR
course of variable duration (Weinshenker 1989), 50% within 10
years from the disease onset, and more than 80% within 25 years,
enter the secondary progressive (SP) form. This is characterized by
a slow progression of the neurological disability. Fifteen per cent
of MS patients have a primary progressive form (PP), character-
ized from the onset by a slow worsening of neurological deficits
without experiencing attacks. A classification of MS phenotypes
(Lublin 1996) includes another form, named progressive relapsing
(PR) MS, which is characterized by a progressive course from the
beginning of the disease with relapses and continuing progression
between relapses.
Description of the intervention
Although the etiology of MS is unknown, there are some available
treatments to cure its manifestations.
• High doses of steroids are used to speed up the recovery from
acute relapses.
• Interferon (IFN) beta-1a, interferon (IFN) beta-1b and glati-
ramer acetate (GA) are used to reduce the attack rate, themagnetic
resonance imaging (MRI)-measured disease activity of frequency
of enhancing lesions, and the increase of MRI lesion burden in
RRMS patients. Although they have recently been licensed in sev-
eral European countries as drugs to treat progressive MS patients,
their long-term efficacy is still debatable and additional data are
needed (Filippini 2003).
• More recently, a monoclonal antibody (natalizumab) and the
first oral treatment (fingolimod) have been licensed to be used in
RRMS (Kieseier 2011).
• Several drugs are used to treat symptoms related to MS
such as spasticity, ataxia, fatigue, pain, urinary disturbances, etc.
(Thompson 2010).
• As regards mitoxantrone, it was approved in 2000 by the United
States Food and Drug Administration (FDA 1999) for the treat-
ment of progressive MS. The indication was “for reducing neu-
rological disability and/or the frequency of clinical relapses in pa-
tients with secondary progressive, progressive relapsing or wors-
ening relapsing-remitting multiple sclerosis”. In March 2005, the
FDA added a ’black box’ warning about cardiotoxicity and ther-
apy-related acute leukaemia (TRAL) and in July 2008 recom-
mended that MX-treated patients receive annual cardiac func-
tion testing after MX therapy. Moreover, there are additional
concerns about the risk of TRAL, as shown by different long-
term follow-up studies (http://www.fda.gov/Drugs/DrugSafety/
PostmarketDrugSafetyInformationforPatientsandProviders/
ucm126445.htm, accessed 20th August 2012).
How the intervention might work
Mitoxantrone (MX) is a cytotoxic agent of the anthracenedione
family, which acts by intercalating with DNA and inhibiting the
topoisomerase II enzyme activity for DNA repair (Durr 1983;
Smith 1983). It has immunosuppressive properties by reducing
the number of B cells, inhibiting T helper cell function, and aug-
menting T cell suppressor activity. MX is widely used for treat-
ment of breast cancer and leukaemias. It is nowadays approved in
50 different countries for treatment of severe tumours, including
advanced breast cancer, hepatoma, non-Hodgkin lymphoma and
others.
A well known side effect is cardiotoxicity, seen in 3% to 4% of
patients treatedwith high cumulative doses ofMX, and apersistent
decrease of circulating white cells and platelets.However, this drug
shows considerably less acute toxicity (nausea, vomiting, alopecia)
than other chemotherapy agents (Sibley 1996).
The first observations of the efficacy of MX in MS derived
from studies performed in experimental allergic encephalomyelitis
(EAE), which represents the animal model of MS, showing that
intravenous administration of the drug was able to suppress disease
evolution (Lublin 1987). MX efficacy in MS can be explained by
different effects on the immune system:
1) down regulation of CD4 cells (Fidler 1985);
2) suppressive effects on different B cell functions, such as antigen
presentation, antibody-dependent demyelination, and comple-
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ment mediated myelinolysis (Fidler 1986a; Levine 1986; Mustafa
1993);
3) inhibition of the demyelinating activity of macrophages (
Watson 1991);
4) proliferation of nonspecific suppressor T cells (Fidler 1986b).
Compared with other immunosuppressants, MX determines a
broad immunosuppression on all the main components of the im-
mune reactions, namely B cells, T cells and macrophages. More-
over,MX is a ’long-acting’ immunosuppressor as it has a long-term
elimination phase with a half-life of nine days, and it is largely se-
questered for an extended period of time (up to one month) in the
deep tissue compartment and is slowly released (Ehninger 1986).
Why it is important to do this review
The experimental evidence of MX efficacy on EAE models was
confirmed in several unblinded pilot clinical studies without ran-
domisation (Capra 1993; Gonsette 1990; Kappos 1990; Krapf
1995; Mauch 1999; Noseworthy 1993; Rees 1998), not consid-
ered in the present review.
Despite the evidence of cardiotoxicity (~12% risk of systolic dys-
function) and leukaemia (~0.8% risk of TRAL) related to MX
administration, a recent evidence report drafted by the American
Academy of Neurology (Marriott 2010) supported the efficacy of
the drug in RRMS, SPMS and PRMS and suggested including it
among the available drugs.
Thus, a systematic review is warranted to verify the effectiveness
and safety of MX use in clinical practice for MS patients.
O B J E C T I V E S
The objective of the review was to determine the efficacy and sa-
fety of mitoxantrone as an immunosuppressive therapy in patients
affected by RR, PR and SP MS. The primary hypotheses to be
tested were whether MX treatment:
1) is effective in reducing progression of disability;
2) has an acceptable safety profile.
The secondary hypotheses to be tested were whether MX is effec-
tive in:
1) reducing the relapse rate;
2) improving patient’s related quality of life;
3) reducing the number of brain magnetic resonance imaging
(MRI) ’active’ lesions;
4) reducing the accumulation of brain MRI lesion burden.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised, double-blinded, controlled trials (RCTs) compar-
ing the administration of MX versus placebo or MX plus steroids
treatment versus placebo plus the same additive therapy (that is,
steroids) were included. Uncontrolled or non-randomised trials
were excluded. Trials in which two different active agents were
compared (for example, mitoxantrone versus interferon or glati-
ramer or methylprednisolone) were excluded.
Types of participants
Adult patients with a clinically definite diagnosis of MS, according
to Poser (Poser 1983) or McDonald criteria and further revisions
(McDonald 2001; Polman 2005; Polman 2011) criteria, affected
by a RR, SP or PR course regardless of age, sex, degree of disability
and duration of the disease. We excluded patients with primary
progressive (PP) MS.
Types of interventions
MX versus placebo or MX plus steroids treatment versus placebo
plus steroids.
Any trial was evaluated, independent of dosage, route of admin-
istration, frequency of administration and duration of treatment.
Types of outcome measures
Primary outcomes
The primary outcome measures were as follows.
1) Number of participants who had confirmed disability progres-
sion at one year and after, from the inclusion into the trial. Dis-
ability progression was defined as an increase of at least 1 point
above the entry score if baseline score < 5.5, and of at least a half-
point if baseline score > 5.5, of the Kurtzke Expanded Disability
Status Scale (EDSS) (Kurtzke 1983), assessed in two different and
subsequent neurological examinations separated by at least a six
month interval free of relapses.*
2) Number of participants who withdrew from the study because
of major side effects of the drug, considered as those side effects
causing death or hospitalisation of the participant.
* Please note: at the time we assessed the data for this review, we
realised that the definitions and measures of disability progression
varied between the included trials. Therefore, we decided to per-
form, in addition to the originally planned analyses, additional
analyses accepting the definitions of disability given in the original
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papers and to include this outcome here, with due allowance for
its post hoc nature.
Secondary outcomes
The secondary outcome measures were:
1) mean change in expanded disability status scale (EDSS) in the
allocated treatment groups at one year and longer;
2) patients with no relapses at six months or one year and after;
3) annualised relapse rate at six months or one year and after;
4) mean and standard deviation (SD) for changes in total area or
volume on brain MRI scans at six months or one year and longer
from the inclusion into the study (Filippi 1998);
5) number of ’active’ lesions, defined as the number of T1 enhanc-
ing lesions on MRI scans at six months or one year and two years;
6) number of participants with ’active’ lesions at six months or
one year and longer from the inclusion into the study;
7) frequency of major (cardiotoxicity; major haematological ab-
normalities) and minor (nausea; vomiting; alopecia; urinary in-
fections) side effects during the follow-up period;
8) abnormal laboratory values.
Search methods for identification of studies
A systematic search without language restrictions was conducted.
Electronic searches
The Review Group’s Trials Search Co-ordinator searched the
CochraneMultiple Sclerosis and Rare Diseases of theCentral Ner-
vous System Group Trials Register (23 May 2013) which, among
other sources, contains:
1. The Cochrane Central Register of Controlled Trials (CEN-
TRAL) (recent issue)
2. MEDLINE (PubMed) (1966 to 23 May 2013)
3. EMBASE (Embase.com) (1974 to 23 May 2013)
4. CINAHL (Ebsco host) (1981 to 23 May 2013)
5. LILACS (Bireme) (1982 to 23 May 2013)
6. PEDro (1990 to 23 May 2013)
7. Clinical trials registries (http://clinicaltrials.gov).
8. WHO International Clinical Trials Registry Portal (http://
apps.who.int/trialsearch/)
Information on the Group’s Trials Register and details of search
strategies used to identify trials can be found in the ’Specialised
Register’ section within the Cochrane Multiple Sclerosis and Rare
Diseases of the Central Nervous System Group’s module. The
search terms are listed in Appendix 1.
Searching other resources
a) Reference lists from identified trials and reviews of multiple
sclerosis treatment (completed April 2005);
b) Handsearch of recent (1996 to 2005) main neurology journals,
abstracts of main neurological and multiple sclerosis congresses
and symposia (ENS; ECTRIMS) conference proceedings;
c) Contact with pharmaceutical companies
producing the drug [Amgen (www.amgen.com/); Merck-Serono
(www.merckserono.co.uk/en/index.html)];
d) Contact with authors of selected articles.
Data collection and analysis
Selection of studies
Three review authors (FMB,MR, RC), with clinical experience in
MS, MRI and the epidemiological field, independently read and
selected articles. A senior reader (GC) resolved any disagreement
through discussion.
For the most recent update, two review authors (FMB, LV) inde-
pendently assessed titles and abstracts of studies resulting from the
searches and decided which articles to collect. They obtained full
copies of all relevant and potentially relevant studies, those appear-
ing to meet the inclusion criteria, and those for which there were
insufficient data in the title and abstract to make a clear decision.
The two review authors then independently assessed full texts and
resolved any disagreement on the eligibility of the included studies
through discussion, achieving a final consensus.
Data extraction and management
Review authors (FMB, LV,MR, RC) independently extracted data
from studies meeting the inclusion criteria. Using a standardised
data collection form, for each trial they independently extracted
data concerning participants, interventions, clinical andMRI out-
come measures performed at different follow-up times, frequency,
type and severity of side effects. The same review authors evaluated
the quality of the trials using the Cochrane Handbook for System-
atic Reviews of Interventions. The extracted data were checked for
agreement between the reviewer authors and discrepancies were
resolved by a joint discussion. The following details were extracted:
1) study design;
2) characteristics of study participants (clinical baseline character-
istics, specific inclusion and exclusion criteria, clinical setting);
3) number and distribution of patients who dropped out or with-
drew;
4) a full description of the therapeutic intervention;
5) clinical outcome measurement instruments, clinical outcomes
and scores (disability or exacerbation) at specified follow-up times;
6) type and the severity of adverse events, and numbers of patients
who discontinued treatment because of adverse events.
Review authors also extracted data on the number of participants
in the allocated treatment groups and for each outcome event,
irrespective of compliance and exclusion from treatment or follow-
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up because of any other reason, in order to perform an intention-
to-treat analysis. We contacted authors to clarify data and check
for any subsequent data as yet not reported.
Assessment of risk of bias in included studies
Two review authors (FMB, LV) independently judged trial quality
and reported the results of trial quality assessment in the ’Risk of
bias’ tables according to the Cochrane Handbook for Systematic Re-
views of Interventions (Version 5.1.0, Table 8.5.d) (Higgins 2011).
Any disagreement was resolved by discussion to reach consensus.
The following domains were assessed as ’Low risk’, ’Unclear risk’
or ’High risk’:
1. random sequence generation (selection bias);
2. allocation concealment (selection bias);
3. blinding of outcome assessment (detection bias);
4. incomplete outcome data (attrition bias), defined as ’High
risk’ when the percentage and reasons for losses to follow-up
were unbalanced between arms;
5. other bias.
Measures of treatment effect
The data analysis was performed using Review Manager software
5 (Review Manager 2013). For each outcome we calculated a
weighted treatment effect across trials.
Binary outcomes were analysed calculating odds ratio (OR) and
risk difference (RD) for each trial separately at different follow-up
periods, with uncertainty in each result expressed using the relative
95% confidence interval (CI). Thus, results were expressed as a
weighted estimate of OR with the relative 95% CI.
Continuous outcomes were analysed for each trial separately using
mean difference (MD) and its standard deviation (SD); MD with
the relative 95% CI and the mean weighted difference across all
trials were considered.
Dealing with missing data
We attempted to retrieve missing data from the authors of the
studies and from the drug companies licensing the drug (Merck-
Serono).
Assessment of heterogeneity
Homogeneity between trial resultswas tested using a standardChi2
test, andwe rejected homogeneity if the P valuewas <0.10. Afixed-
effect model approach (Yusuf 1985) was utilised in combining
the trial outcomes in case of homogeneity between trials; in case
of heterogeneity, a random-effects model was used (DerSimonian
1986).
Data synthesis
Results were expressed as a weighted estimate of OR with the
relative 95% CI for binary outcomes. For continuous variables,
MDwith the relative 95%CI andmeanweighted difference across
all trials were considered. In the absence of heterogeneity, a fixed-
effect model was used.
Subgroup analysis and investigation of heterogeneity
Different definitions of disability progression were reported in in-
cluded studies. Therefore, we decided to perform analysis on dis-
ability progression by using two different definitions: six month
only confirmed disability progression (pre-planned analysis); ei-
ther three or six month confirmed disability progression (post hoc
analysis).
Sensitivity analysis
Due to the high rate of dropouts, we decided to perform a sensitiv-
ity analysis to explore the effect of withdrawn and lost to follow-
up patients on the major outcomes. The best case scenario (with
regards to treatment) assumed that none of the patients who were
excluded from the analysis in the MX-treated group had the un-
favourable outcome of interest, while all those excluded from the
control group did have, and vice versa for the worst case scenario.
The likely scenario assumes that all of the placebo andMX-treated
participants who were excluded had the outcome of interest.
R E S U L T S
Description of studies
Salient characteristics of the design, participants, interventions,
and outcomes of the studies meeting the inclusion criteria are
summarised in the table Characteristics of included studies.
Results of the search
Twohundred and seventy-five articles were identified by the search
strategy, up to 23 May 2013 (Figure 1). Of these, 18 were se-
lected as full papers assessing the efficacy of MX in MS patients.
Thirteen studies were excluded and three were included (Edan
1997; Hartung 2002; Millefiorini 1997); the remaining two ar-
ticles Nadeau 2006 and Krapf 2005 were classified as secondary
references of an already included RCT (Hartung 2002).
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Figure 1. Flow diagram up to 23 May 2013.
7Mitoxantrone for multiple sclerosis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Please note that on August 2012, after reviewing one of the pre-
viously included paper (Van de Wyngaert 2001), we decided to
exclude this trial from the analysis due to the absence of a clean
placebo group (it was treated with steroids, not added in the treat-
ment arm) (Martinelli Boneschi 2013).
Included studies
Three trials contributed to this review. They were published be-
tween 1997 and 2002: Edan 1997,Millefiorini 1997 andHartung
2002. It is worth mentioning that Edan 1997 was published
three years after the end of the recruitment period of the trial,
Millefiorini 1997 four years later and Hartung 2002 seven years
later. A total of 221 participants contributed to the present re-
view, of whom 111 were assigned to MX and 110 to placebo;
Hartung 2002 accounted for 58% of the total number of partici-
pants. Withdrawals and losses to follow-up are shown in Table 1.
Participants
All studies recruited patients affected by definite MS (McDonald
2001; Poser 1983). The disease course and disability status in-
clusion criteria were different across studies. In Edan 1997 they
were RR participants with at least two exacerbations with sequelae,
which corresponds to the definition of worsening relapsing-remit-
ting MS patients, or SP participants with progression of at least 2
points on the EDSS scale in the year before the inclusion; partici-
pants had a baseline EDSS lower than 6.0 and at least oneMRI ac-
tive lesion during a baseline observation period two months prior
to randomisation. Millefiorini 1997 recruited RR patients with at
least two attacks in the previous two years and EDSS between 2.0
and 5.0. Hartung 2002 randomised SP participants, defined as
“patients with a gradual progression of disability with or without
superimposed clinical relapses”, or PR, defined as “patients with a
stepwise progression of disability between clinical relapses”, who
would have been more properly defined as worsening RRMS pa-
tients, with progression of at least 1 EDSS point in the preceding
18 months and baseline EDSS between 3.0 and 6.0. Four partici-
pants in the Hartung 2002 study were randomised but they never
received the treatment.
Disease duration was less than 10 years in Edan 1997 and
Millefiorini 1997, while it was not specified inHartung 2002. The
lower age limit was 18 years in all the studies, and was up to 45
years (Millefiorini 1997) or 65 years (Edan 1997; Hartung 2002).
Exclusion criteria were similar in all of the studies: pregnancy, use
of immunosuppressive drugs in the previous three months, and
use of steroids in the previous month. A left ventricular ejection
fraction (LVEF) lower than 50% was also an exclusion criterion
in Hartung 2002 and Millefiorini 1997.
Interventions
In all the studiesMXwas the active drug, apart from theEdan 1997
study in which MX was given with steroid therapy. The placebo
was a sham drug apart from Edan 1997 in which the placebo arm
was a short course of steroids (1 g /month of intravenous methyl-
prednisolone).However, different dosages and time scheduleswere
used in the studies: Edan 1997 gaveMX in 6 pulses of 20mg every
month for 6 months, which corresponded to a total dosage of 120
mg or approximately 72 mg/m2 of body surface over 6 months.
Millefiorini 1997 used 12 pulses of 8 mg/m2 body surface every
month for 1 year, which corresponded to a total dosage of 96 mg/
m2 of body surface over 1 year. Hartung 2002 used 8 pulses of
12 mg/m2 body surface every 3 months for 2 years, which corre-
sponded to a total dosage of 96 mg/m2 body surface over 2 years.
Regarding this study, we decided to exclude the intermediate arm
of 5 mg/m2 body surface as it used a different dosage from the
others (total dosage of 40mg/m2 body surface over 2 years), which
was difficult to compare. This trial allowed an adjustment of the
dosage in the case of leucopenia, thrombopenia, infections within
three weeks after MX administration, or reduction of the LVEF.
As a consequence, the mean cumulative MX dose at the end of the
Hartung 2002 study was 82.6 mg/m2 instead of the pre-planned
96 mg/m2.
Outcomes
In two of the three studies, the primary outcome was a clinical
measure, while in Edan 1997 the primary outcome was an MRI
measure.
Disease progression
The disease progression was measured by using two different out-
comes: the proportion of participants with confirmed disease pro-
gression at the end of the study, and the difference in disability
between the end and the beginning of treatment as assessed with
the EDSS scale.
With reference to the primary outcome of this review, different
definitions were made across the different studies. In Edan 1997,
disease progression was defined as a two month confirmed 1.0
point EDSS increase between baseline and the end of the study if
the baseline EDSS was ≤ 5.5, or a 0.5 point EDSS increase if the
baseline EDSS was > 5.5. The authors specified that the increase,
if present, was measured for two months running at the end of the
study and according to the intention-to-treat (ITT) principle. In
Millefiorini 1997, disease progression was defined as an increase of
at least 1.0 point on the EDSS scale, which needed to be confirmed
at a three month follow-up (personal communication with one
of the study authors), irrespective of baseline EDSS. In Hartung
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2002, disease progression was defined as a six month and three
month confirmed deterioration of at least 1 EDSS point between
baseline and the end of the study; for the purposes of the present
study, we decided to use the six month confirmed progression as
a more reliable measure of disease progression.
Analyses on disability progression were performed by using two
different definitions: six month only confirmed disability progres-
sion (pre-planned analysis) and either three or six month con-
firmed disability progression (post hoc analysis). As regards the six
month confirmed disability progression, only Hartung 2002 pro-
vided data for the two year follow-up, while for the post hoc anal-
yses Millefiorini 1997 also provided data for the one and two year
follow-up. Edan 1997 was not included in any of these analyses
as the duration of the follow-up of six months was considered to
be too short an interval for the assessment of disease progression.
Looking at the difference in disability between the final and base-
line evaluations as measured with the EDSS, Millefiorini 1997
provided data on a subgroup of participants for the one year fol-
low-up, while Millefiorini 1997 and Hartung 2002 provided data
for the two year follow-up. Edan 1997 provided data for a six
months interval, which was considered too short an interval of
time and therefore was not included.
Relapse frequency
Relapse frequency was assessed by reporting the proportion of par-
ticipants free from relapses and the annualised relapse rate. Two
definitions of relapse, “the occurrence of symptoms of neurologi-
cal dysfunction lasting more than 48 hours and preceded by sta-
bility or improvement for at least 30 days” (Edan 1997); and “the
appearance of a new symptom or worsening of an old symptom,
attributable to MS, accompanied by a documented new neuro-
logical abnormality, lasting more than 48 hours and preceded by
stability or improvement for at least 30 days” (Millefiorini 1997),
were judged very similar. Hartung 2002 gave a definition only
for severe relapses (“the occurrence of new symptoms lasting for
longer than 48 hours with a change in functional system score of
more than 2 points, or a deterioration of at least 1 point in at
least 1 of the 4 following systems: pyramidal, brainstem, cerebellar
or visual”), which had to be treated, by protocol, with a five day
course of steroids.
Regarding the proportion of participants with no relapses, Edan
1997 and Millefiorini 1997 provided data for the six months to
one year follow-up period, and Hartung 2002 and Millefiorini
1997 after two years of follow-up.
With respect to annualised relapse rate, all of the studies provided
data at the one year and two year follow-up except for the Edan
1997 study.
Other clinical outcome measures were assessed in Hartung 2002,
such as the number of days of hospitalisation due to MS and the
use of wheelchair assistance, as well as the quality of life by means
of the Stanford health assessment questionnaire (Ramey 1992).
Magnetic resonance imaging (MRI) outcome
For the present study, we defined the active lesions, and conse-
quently the proportion of participants with active lesions, as le-
sions which were enhanced after gadolinium injection at the fol-
low-up period. We decided not to include the number of new or
enlarged T2 lesions, even if they have to be considered as active
lesions, for the following reasons:
1) not all of the studies provided data on that measure;
2) the measurement of T2 lesions is not considered a valid and
robust outcomemeasure as it typically shows a high variability and
it is weakly correlated with clinical measures (Filippi 2001);
3) in the absence of raw data, we assumed that the new or enlarged
T2 lesions were replicated by the enhancing lesions, and that it
was sufficient to measure either one of the two measures.
MRI provided the primary outcome measure in Edan 1997. This
was the proportion of participants who developed new T1-en-
hancing lesions on serial monthly gadolinium scans. The number
of new enhancing lesions per participant per month and the mean
number of new T2-weighted lesions at the end of the trial were
used as secondary outcome measures. In Millefiorini 1997, the
number of total enhancing lesions at the 12 month follow-up and
the number of new or enlarged T2 lesions at the 12 month and
24 month follow-up were measured in a subgroup of patients (n
= 25). In a subgroup of 110 participants not demographically and
clinically different from the original cohort group, Hartung 2002
assessed the numbers of T1 hypointense, T2 hyperintense and
gadolinium-enhancing lesions; the T2 lesion load was estimated
using a scoring system (Edan 1997; Miller 1991).
For Millefiorini 1997 and Hartung 2002, data were provided by
study authors contacts.
Side effects and adverse events
Side effects and minor and major adverse events were reported
in all studies. However, the occurrence of an adverse event was
reported when present at least once, irrespective of how many
times it appeared. Moreover, it was impossible to know the time
of appearance of the adverse event, whether early in the course
of therapy or late, because this was not reported in any of the
studies; as well as the time of dropping out due to the occurrence
of adverse events. Millefiorini 1997 declared that self-reporting
was used as adverse events monitoring (judged to be a risk of bias);
no information was provided by the other included RCTs.
Echocardiographywas performed at the baseline and the endof the
study in Edan 1997; at baseline, six and 12 months in Millefiorini
1997; before treatment and once a year in Hartung 2002 (MX
was interrupted if the LVEF decreased by more than 10% from
baseline, or below 50%).
Excluded studies
From the search strategy (up to May 2013), 13 articles were ex-
cluded for the following reasons: seven were open-label studies
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(Capra 1993; Gonsette 1990; Kappos 1990; Kornhuber 1992;
Krapf 1995; Noseworthy 1993; Rees 1998), four were observa-
tional safety and efficacy studies (Edan 2001; Goodkin 2001;
Mauch 1999; Hamzehloo 2007) and one was an RCT with an
absent placebo group (Edan 2011).
Regarding open-label studies, they all demonstrated that MX re-
duced the progression of disability, using different dosages and
intervals of administration. Gonsette 1990 used 14 mg/m2 every
3 weeks; Kornhuber 1992 12 mg/m2 every 3 weeks; Kappos 1990
10 mg/m2 every 3 weeks, Capra 1993 6 to 10 mg/m2 every 3
months, and Rees 1998 12 mg/m2 every 3 months. On the con-
trary, Noseworthy 1993 found that the progression of disability
in MX-treated patients at a dosage of 8 mg/m2 every three weeks
for a total of seven infusions was not significantly different from
that of two historical MS control groups. Krapf 1995 focused on
MRI outcomes, and they firstly showed that the total number of
MRI-enhancing lesions dramatically decreased after MX therapy,
from a total of 169 to 10 after one year and to five after two years
of treatment in a series of patients affected by RR (six patients)
and SP (four patients). Regarding the observational safety cohort
studies (Edan 2001; Goodkin 2001; Mauch 1999; Hamzehloo
2007), they followed up MS patients who had been previously
treated with MX to assess the long-term safety and efficacy of the
drug (Edan 2001; Mauch 1999), and a registry has been devel-
oped (Goodkin 2001) to evaluate andmonitor MX long-term car-
diotoxicity. Hamzehloo 2007 reported a non-randomised clinical
trial 129 on patients (93 females; 108 RRMS and 21 SPMS) who
received the treatment regimen of mitoxantrone 12 mg/m2 intra-
venously every 3 months for 12 months.
Edan 2011 was excluded because a clean placebo arm was lacking
(MX monthly plus 1 g of methylprednisolonefor 6 months fol-
lowed by IFN for other 27 months versus IFN for 3 years plus 1 g
of methylprednisolone monthly for the first 6 months).
On August 2012, the review authors decided by common consent
to exclude a study (Van de Wyngaert 2001) previously included.
The reason for exclusion lay in the fact that this RCT didn’t meet
full criteria for inclusion, because a course of steroids (1 g /month
of intravenous methylprednisolone) was added during the first
three months of the trial to either arm, and then given only to the
placebo group and not concurrently to the treatment group.
Van deWyngaert 2001 compared 49patients (28MX12mgversus
21 methylprednisolone) administering agents once a month for
the first three months and then every three months until month
32. In this trial, moreover, the disease course of recruited patients
was not completely clear, defined as ’relapsing, secondary MS’,
with a progression of at least 1 point of EDSS in the preceding
year and baseline EDSS between 3.0 and 6.0. We believe that
they corresponded to the worsening RR, PR or SP course. Disease
progression was defined as a 1.0 point EDSS increase if baseline
EDSS was < 5.5 and a 0.5 point increase if baseline EDSS was
≥ 5.5, and no clinical confirmation seemed to be required. A
definition of relapse was not provided.
Risk of bias in included studies
Risk of bias assessments are summarised in Figure 2 and Figure
3. See the Characteristics of included studies tables for detailed
quality assessments of each included study. Overall, no studies
were judged as completely free of risk of bias.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 3. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Allocation
Millefiorini 1997was judged as ’Low risk’ of bias. Edan 1997 didn’t
provide enough information to judge the method to implement
sequence generation, and Hartung 2002 didn’t provide a good
description of the method used for allocation; these studies were
judged as ’Unclear risk’ for the respective outcome.
Blinding
For Hartung 2002 andMillefiorini 1997 blindness was judged ad-
equate, while Edan 1997 was judged at ’High risk’ of bias because
“neither the patients nor the clinical investigators were blinded
during the study”; however, the primary outcome was aMRI mea-
sure and the two MRI observers were blinded.
Incomplete outcome data
In Hartung 2002 and Millefiorini 1997, losses to follow-up were
similar in number and the reasons between arms; Edan 1997 was
judged at ’High risk’ of bias because it had five participants lost
to follow-up “due to pronounced clinical worsening”, all in the
methylprednisolone group.
Selective reporting
Even if a published protocol was unavailable, no study was judged
at ’High risk’ of bias because it was clear that the published reports
included all expected outcomes, including those pre-specified.
Other potential sources of bias
Different reasons contributed to judging Edan 1997 and
Millefiorini 1997 at ’High risk’ of bias (see ’Risk of bias’ tables in
Characteristics of included studies).
Effects of interventions
Primary outcomes
1) Number of participants who had confirmed disability
progression
Patients with six months confirmed disability progression over one
year: no data were available when considering this definition of
confirmed disease progression.
Analysis 1.1 Patients with sixmonths confirmed disability progres-
sion over two years: data from 128 participants in Hartung 2002
(58% of the total) were available. An overall 16/128 progressed
over two years, 4/63 in the MX group and 12/65 in the placebo
group. This corresponded to a sustained overall efficacy of the
drug on the progression of disability (OR 0.30, 95% CI 0.09 to
0.99). However, when performing the sensitivity analysis to take
into account the four participants who were not included in the
intention-to-treat (ITT) analysis (Hartung 2002), the efficacy of
the drug disappeared in the worst case and in the likely scenario.
Longer follow-up (three years) was available in a subgroup of par-
ticipants (Hartung 2002): 6/42 (14%) MX-treated participants
versus 16/40 (40%) placebo-treated participants had a confirmed
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progression of disease. However, these data were not included in
the present review as they were not collected according to an ITT
analysis.
Analysis 1.2 Post hoc analysis: patients with three or six month
confirmed disability progression: at one year only data from
Millefiorini 1997 were available for 51 participants (23% of the
total) of whom eight progressed, two in the MX group and six
in the placebo group, leading to an OR of 0.24 (95% CI 0.04 to
1.33; P = 0.1).
At two years, data from two trials (Hartung 2002; Millefiorini
1997) and 179 participants (81% of the total) were available for
the analysis: 27 participants (12% of the total) progressed over
two years (6 patients in the MX group and 21 in the placebo
group). This corresponded to a sustained overall efficacy of the
drug on the progression of disability (OR 0.23, 95% CI 0.09 to
0.59; P = 0.002). The efficacy was present irrespective of follow-
up duration, dose and frequency of therapy as no heterogeneity
across trials was found. When performing the sensitivity analysis
to take into account the four participants who dropped out of the
Hartung 2002 study and were not considered in the ITT analysis,
the efficacy of the drug persisted in all the different scenarios (likely
scenario: OR 0.34, 95% CI 0.15 to 0.78; P = 0.02).
Finally, Hartung 2002 was the only included RCT that reported
data on quality of life. The mean change in the Stanford health
assessment questionnaire index was small for the arms over the
24 months of the study. The placebo group mean score increased
by 0.26, with significantly less change observed in the 12 mg/m
2 mitoxantrone group (0.09; P = 0.024). Thus, more patients in
the placebo than in the 12 mg/m2 mitoxantrone group showed
deterioration in the health assessment questionnaire index (41
versus 25, P = 0.012), consistent with the lower deterioration
measured in this study by the EDSS for the treatment arm.
2) Patients who withdrew from the study because of major
side effects of the drug (Analysis 1.3)
Data were available for all of the studies, including all participants.
While Edan 1997 and Millefiorini 1997 declared that no partic-
ipants were lost to follow-up because of major side effects of the
drug, Hartung 2002 reported five treated participants (3.2% of
the total) versus two (0.9%) in the placebo group as losses. Rea-
sons are listed in Table 1. No death, symptomatic cardiac events
or tumours were reported during the treatment period.
Secondary outcomes
Clinical outcomes
1) Mean change in Expanded Disability Status Scale
(Analysis 2.1)
At six months or one year, a subgroup of participants enrolled in
Millefiorini 1997 (11% of the total) were available for the analysis.
The effect of treatment on the patients’ disability was not statisti-
cally significant (MD -0.35, 95% CI -0.86 to 0.16).
At two years, 175 participants (79.2% of the total) enrolled in
Hartung 2002 and Millefiorini 1997 were available for the out-
come. The effect of treatment on the patients’ disability was sta-
tistically significant (MD -0.36, 95% CI -0.7 to -0.02; P = 0.04)
based on a single study as no dispersion measures were provided
for Millefiorini 1997.
2) Patients with no relapses
Analysis 2.1 At six months or one year, 93 participants (42.1%
of the total) from Edan 1997 and Millefiorini 1997 were avail-
able. Forty-five participants did not experience any relapses at six
months or one year follow-up (33 MX-treated and 13 placebo-
treated participants). As the two outcomes were measured at a dif-
ferent follow-up interval, we calculated an OR using a random-
effects model (data not shown); the OR of the two studies was
5.39 (95% CI 2.21 to 13.15; P = 0.0002) suggesting an important
role of MX in relapse rate reduction.
Analysis 2.3 At two years, data from 179 participants (81% of the
total) were provided byMillefiorini 1997 and Hartung 2002. Sev-
enty-nine of them didn’t have any relapse at the two year follow-up
(51MX-treated patients and 28 placebo-treated patients); the OR
was 2.82 (95% CI 1.54 to 5.19; P = 0.0008). When performing
the sensitivity analysis to take into account the four participants
who dropped out from Hartung 2002 and were not included in
the ITT analyses, the efficacy of the drug was confirmed under all
the different scenarios (likely scenario: OR 3.11, 95% CI 1.68 to
5.72; P = 0.0003).
3) Annualised relapse rate (Analysis 2.4)
At six months or one year, 217 participants (98.2% of the total)
from the included studies were available for the present outcome.
In all of the studies there was a reduction in the annualised relapse
rate in MX-treated versus placebo-treated participants. However,
as no dispersion measures were available for the other trials, only
data fromMillefiorini 1997 and 52 participants were used for the
analysis, with a MD of -1.02 (95% CI -1.69 to -0.35; P = 0.003).
At two years, data from 206 participants were analysed, includ-
ing Millefiorini 1997 and Hartung 2002. In both studies there
was a reduction in the annualised relapse rate in MX-treated ver-
sus placebo-treated participants. However, as no dispersion mea-
sure was available for Hartung 2002, only Millefiorini 1997 con-
tributed to the estimate of weighted mean difference (MD -0.85,
95% CI -1.47 to -0.23; P = 0.007).
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Magnetic resonance imaging (MRI) outcomes
4) Mean and standard deviation (SD) changes in total area
or volume on brain MRI scans
No data were available for this secondary outcome measure in any
of the studies. In Hartung 2002 data have been collected but they
are still unpublished.
5) Number of ’active’ lesions (Analysis 2.5)
At six months or one year, 62 participants (28 % of the total) from
Edan 1997 and Millefiorini 1997 provided data for the present
outcome. This number of participants represented a subgroup of
the original cohort of randomised patients. With regard to Edan
1997, no data were available for the five withdrawn participants,
while for Millefiorini 1997 MRI measurements were performed
in a subgroup of participants: MD-0.79 (95% CI -1.68 to 0.09;
P = 0.08). There did not appear to be any heterogeneity between
studies.
At two years, 70 participants (31.7%of the total) were available for
the present outcome from Hartung 2002, reporting 0.03 versus
0.26 in MX- and placebo-treated participants respectively, but no
dispersion measures were available to perform a meta-analysis.
6) Number of participants with ’active’ lesions (Analysis 2.6)
At six months or one year, a total of 132 participants (59.7%
of the total) were included from Edan 1997, Hartung 2002 and
Millefiorini 1997 (data provided by study authors). Thirty-five of
132 (26.5%) had active lesions at six months to one year follow-
up (10 MX-treated and 25 placebo-treated participants). MX was
found to be effective in reducing the proportion of participants
with active lesions (OR 0.24, 95% CI 0.10 to 0.57; P = 0.001).
At two years, only participants from the Hartung 2002 study were
included; 0% ofMX-treated and 13.5% of placebo-treated partic-
ipants had active lesions at two year follow-up, leading to an OR
of 0.09 (95% CI 0.00 to 1.77).
Side effects
7) Frequency of major and minor side effects
No heterogeneity was found across the different trials, suggesting
that the risk of adverse events was not related to the different
treatment regimens used in the different studies.
Amenorrhea and persistent amenorrhoea (Analysis 3.1)
Amenorrhea was developed during therapy by 35% ofMX-treated
female participants and by none of the placebo-treated female
participants. For most of the participants the amenorrhoea dis-
appeared after discontinuation of MX therapy; however, in six
women (12% of the total) amenorrhoea was still present after the
end of treatment: in five participants in Hartung 2002 at the one
year follow-up examination after the end of therapy, and in one
participant in Edan 1997 at an undefined follow-up visit after the
end of therapy.MX-treated female participants had anOR of 22.3
(95% CI 4.03 to 123.47; P = 0.0004) of developing amenorrhoea
compared with placebo-treated participants; the risk was higher
in Edan 1997 and Hartung 2002 than in the Millefiorini 1997
study. Persistent amenorrhoea had an OR of 8.27 (95% CI 1.02
to 67.18; P = 0.05); Millefiorini 1997 declared no events for this
outcome.
Symptomatic cardiac events and cardiotoxicity (LVEF
reduction below 50%)
Regarding cardiotoxicity, there was a quite similar definition across
the different trials, which was the decrease of LVEF below 50%.
Edan 1997 andMillefiorini 1997 excluded any case of cardiotoxi-
city, despite very careful cardiac monitoring, by means of the elec-
trocardiogram and echocardiography. In Hartung 2002, cardiac
monitoring was performed at baseline and once a year by means
of echocardiography; two MX-treated participants showed a de-
crease in LVEF to below 50% at the three year follow-up (namely,
one year after the end of the treatment) which was not present
at the end of the treatment and one interrupted the treatment
after four doses of the drug because of decreased LVEF, but no
clinically significant cardiac dysfunction developed in any of the
treated participants.
An LVEF reduction, lower than 50%, was observed in 3/110
(2.7%)of MX-treated participants (Hartung 2002), resulting in
discontinuation of therapy in three of them.However, none of the
treated participants developed clinically significant cardiac events
at least one year after the end of MX treatment.
Nausea and vomiting (Analysis 3.2)
It was reported by 62/110 MX-treated participants (56.3%) and
by 13/109 (13%) of placebo-treated participants. Therefore, MX-
treated participants had a risk which was 14.01 times greater (95%
CI 6.36 to 30.85; P < 0.00001) than for placebo-treated partici-
pants of developing nausea and vomiting during the administra-
tion of the drug. In Hartung 2002 one participant stopped the
treatment because of repeated episodes of nausea and vomiting
that persisted despite symptomatic treatment and decreases inMX
dosage (FDA 1999).
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Alopecia (Analysis 3.3)
It was reported by 50/110 MX-treated participants (45.5%) and
by 20/109 (18.3%) placebo-treated participants. MX-treated par-
ticipants had a 4.65 times greater risk (95% CI 2.37 to 9.12; P <
0.0001) than placebo-treated participants of developing alopecia
during the treatment period.
Urinary tract infections
(Analysis 3.4)
Twenty-seven of 110 MX-treated participants (24.5%) and nine
of 109 (8.3%) placebo-treated participants experienced urinary
tract infection during the trials (OR 3.76, 95% CI 1.67 to 8.46;
P = 0.001). One participant in Hartung 2002 interrupted MX
treatment because of repeated urinary infections, and another one
because of moderate renal insufficiency with evidence of urinary
retention and hydronephrosis; this participant recovered after a
surgical intervention of sphincterotomy (FDA 1999).
Respiratory tract infections
(Analysis 3.5)
Forty of 110 MX-treated participants (36.4%) and 35/109
(32.1%) placebo-treated participants experienced respiratory tract
infections during the trials. As none of the episodes led to discon-
tinuation of treatment, we assumed that all of these episodes were
mild to moderate. The difference between the two groups was not
statistically significant (OR 1.34, 95% CI 0.72 to 2.50; P = 0.35).
Headache
(Analysis 3.6)
Headache was reported by 7/110 MX-treated participants (6.4%)
and5/109 (4.6%)placebo-treated participants. The differencewas
not statistically significant (OR 1.36, 95% CI 0.44 to 4.24; P =
0.59).
8) Laboratory side effects
Leucopenia
(Analysis 4.1)
It was difficult to measure the exact frequency and severity of the
occurrence of leucopenia during MX treatment because of the
different definitions across trials and the different time of mea-
surement of white blood cell count after MX administration. In
Edan 1997, the white blood cell count was measured at the next
monthly injection, and a decrease in leucocytes indicative of a
grade two toxicity (according to the WHO) was reported in two
MX-treated participants, without any need for dose adjustment.
All the MX-treated participants were reported in Edan 1997 to
have had a pronounced leucopenia at the so-called ’nadir’ period,
which was about two weeks after each MX cycle. In Millefiorini
1997, haematological examination was performed on a monthly
basis before the next MX cycle and no adverse events were re-
ported. In Hartung 2002, the MX dosage was adjusted according
to the white blood cell count; specifically, MX dosage was reduced
to 10 mg/m2 for infections occurring within three weeks after an
MX infusion if accompanied by a white blood cell count below
2 x 109/L or platelet count of less than 50 x 109/L, or reduced
to 8 mg/m2 for infections occurring within three weeks after an
MX infusion if accompanied by a white blood cell count below 1
x 109/L or platelet count of less than 25 x 109/L. It was, however,
unknown how many participants changed the treatment dosage
because of that, and the occurrence of leucopenia was reported
with no specification of the time of measurement. According to
the Food and Drug Administration (FDA) safety review (FDA
1999), inHartung 2002 adjustments ofMX therapy weremade in
27 out of 60 participants due to leucopenia occurrence, the mean
total MX cumulative dosage was 82.6 mg/m2 (SD 23.1).
Taking into account all of these limitations, 14/83 (16.9%) MX-
treated participants and 0/85 placebo-treated participants devel-
oped leucopenia as measured before the administration of the next
treatment cycle, leading to an OR of 17.95 (95% CI 2.35 to
137.00; P < 0.005). Apparently, none of the cases led to an inter-
ruption of MX therapy.
Anaemia
(Analysis 4.2)
Eight out of 83 (10%) MX-treated participants and 2/85 (2.3%)
placebo-treated participants developed anaemia, resulting in an
OR of 4.51 (95% CI 0.92 to 22.20; P = 0.06).
Increased liver enzymes
Only Edan 1997 and Hartung 2002 reported data on liver en-
zymes. In Edan 1997 there were no cases of abnormal findings.
In the Hartung 2002 article, two different figures were reported:
an increase in gamma glutamyl transpeptidase and an increase in
aspartate aminotransferase, but it was not known whether they
occurred in the same or in different participants. If we postulated
that they were different participants, a total of 9/62 (14.5%) MX-
treated participants and 2/64 (3.1%) placebo-participants showed
an increase of hepatic enzymes. It is worth mentioning that two
participants (one in Edan 1997 and one in Hartung 2002) of the
placebo arm developed hepatitis during the trials.
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D I S C U S S I O N
Summary of main results
In this review, we addressed four different issues.
1) Is MX therapy effective in reducing the progression of
disability and the frequency of clinical attacks?
Our data confirmed the clinical efficacy of MX on disease progres-
sion and relapse frequency in patients affected byMS. Most of the
outcomes, either clinical or MRI-related, supported an efficacy of
MX.
Regarding the proportion of participants with confirmed progres-
sion of disability, due to the different definition of disability pro-
gression across studies we decided to perform post hoc analyses
additional to the originally planned primary outcome measure.
The OR of MX-treated participants versus placebo-treated par-
ticipants at one year was 0.24 (95% CI 0.04 to 1.33) using the
three or six month confirmed definition. As regards the two year
follow-up, the OR was 0.30 (95% CI 0.09 to 0.99) using the six
month confirmed definition (one study, 58% of the participants)
. While admitting that post hoc analysis, which included a less
stringent definition of disability progression, may raise method-
ological issues, it is worthwhile to mention that the difference in
the proportion of patients who experienced disability progression
across the two treatment arms was similar and was confirmed by
using any of these definitions. Moreover, it is still questionable
whether to use the three or six month interval of confirmation
of disability progression, even across Cochrane reviews (in Rice
2001: “disability progression is a sustained (3 or 6 months) in-
crease in EDSS of at least 1 point recorded out of exacerbation”;
in La Mantia 2010: “progression has been defined as a persistent
worsening of at least 1 point in EDSS, recorded out of relapse and
confirmed by a follow-up assessment at 6 months”), and we need
to be more cautious when aggregating data on unconfirmed dis-
ability progression. The use of an interval of three or six months
for a confirmation of disability progression does not substantially
change the results of the Hartung study (Table 3, page 2022) as
the numbers of progressed patients in theMX-and placebo-treated
arms were 5/60 versus 14/64 using the three month interval and
4/60 versus 12/64 using the six month interval.
We also performed sensitivity analyses to consider the few patients
who dropped out from the studies. In Hartung 2002, it was men-
tioned that analyses were performed according to an ITT princi-
ple (page 2022, second column, line 34). However, four patients
(one placebo-treated and three MX-treated) dropped out before
receiving any treatment were not included in the ITT analysis, and
were therefore considered for the sensitivity analyses. The sensi-
tivity analysis influenced the results at the one year but not at the
two year follow-up.
As a general comment, we have also to consider that the EDSS scale
is still the most widely used scale to assess disability progression
in MS. It has many drawbacks, represented by its poor sensitivity
to changes and moderate inter- and intra-observer reliability (
Goodkin 1992). The efficacy of MX in reducing the progression
of disability was less evident when the outcome was the difference
in EDSS score at the end versus the beginning of treatment, even
if a single study was used for the analysis.
MX was effective in reducing the relapse rate (measured as the an-
nualised relapse rate) and in increasing the proportion of patients
free from relapses; the efficacy was not modified by the assignment
of dropped out patients. From available data, however, it is not
possible to ascertain whether the efficacy of MX in reducing the
progression of disability is due to a reduction in the frequency of
clinical relapses or to other reasons. The clinical efficacy of MX
was paralleled by that on MRI-derived outcome measures. When
considering MRI measures of inflammatory activity, such as the
number of active lesions and the proportion of patients with active
lesions (defined as enhancing-lesions on T1 scans), a statistically
significant MX efficacy was found for the latter but not for the
former measure. On the contrary, it was not possible to explore
and aggregate MRI measures of ’neurodegeneration’, such as the
measurement of brain atrophy, as no data were available from the
selected studies.
Admittedly, as a limitation of our meta-analysis, there were many
sources of potential heterogeneity across the different trials repre-
sented by the following.
a) The types of enrolled patients: in Edan 1997, SPwith worsening
disability (progression of at least 2 points on EDSS scale in the
previous year) and worsening RR (two relapses with sequelae in
the previous year) with evidence of MRI inflammatory activity;
in Millefiorini 1997, RR with at least two relapses in the previous
two years; and in Hartung 2002, SP, PR and worsening RR with
evidence of a progression of at least 1 point of EDSS respectively
in the preceding 18 and 12 months.
b) The frequency, interval of administration and total dosage of
the drug: 6monthly cycles of 20 mg combined with 1 g of methyl-
prednisolone in Edan 1997; 12 monthly pulses of 8 mg/m2 of
body surface in Millefiorini 1997; 8 pulses every 3 months of 12
mg/m2 of body surface in Hartung 2002.
c) The addition of steroids to the placebo and active arm in Edan
1997.
However, no major heterogeneity was found according to the sta-
tistical methods used, whichwere planned in the original protocol,
in any of the explored outcome measures. This possibly suggests
that, at least in the short-term period, none of the above variables
acted as effect modifiers or confounders of drug efficacy.We could
also argue that the test used (Cochran’s Q) is poor in sensitivity
when detecting true heterogeneity among studies as being signifi-
cant, especially when few studies are included in themeta-analysis.
Another limitation was the lack of a uniform definition of some
of the explored outcome measures across the different studies, es-
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pecially as regards the definition of confirmed progression of dis-
ability for which a correct time interval of six months was defined
only by Hartung 2002. It is highly warranted to use the same
definition of outcome measures across different trials in order to
make data from different trials most comparable and available for
pooling. Moreover, no data were available from longer follow-up
studies that were able to provide information on long-term drug
effectiveness. There are some data on MX efficacy at three year
follow-up, one year after the end of the trial, in a subgroup of pa-
tients from Hartung 2002. Six out of 42 (16%) MX-treated par-
ticipants and 16/40 (42%) placebo-treated participants showed a
confirmed progression of disease leading to an OR of 0.25 (95%
CI 0.09 to 0.73; P = 0.01). However, these analyses were not per-
formed according to an ITT analysis and, therefore, they have
limited clinical relevance.
2) Which patients should get MX?
As previously reported, the selected participants were different
across studies, even though nomajor heterogeneity has been found
according to the statistical methods used. It is, however, impossible
to establishwhether small differences between trialswere due to the
selected patients or to the different treatment regimens. Gonsette
recently suggested that MX should only be used in patients with
worsening RR, defined as “RR patients experiencing frequent and
disabling relapses likely leading to permanent severe disability”,
and an SP course with evidence of worsening disability, defined as
an increase of at least 1 EDSS point per year (Gonsette 2003).
3) What should be the dosage and frequency of
administration of MX?
No clear indications can be derived from this meta-analysis. A re-
cent review (Gonsette 2003) suggests a treatment regimen with
an induction phase (12 mg/m2 every month for 3 months) fol-
lowed by a maintenance phase (12 mg/m2 every 3 months for 21
months), which seems to be an acceptable trade-off to maintain
treatment for 2 years with a reasonable cumulative dose (120 mg/
m2). This scheme is supported by the in vivo effect of MX admin-
istration on immune cells, which is characterized by a marked im-
munosuppression (namely, leukopenia <2000/mm3 or lymphope-
nia < 1000/mm3) after three to four monthly infusions main-
tained for two years with a subsequent trimonthly administration.
The dosage needs to be adjusted according to the haematological
profiles shown before the next treatment, as reported in Table 2.
It is advisable to adjust the dosage regimen rather than to delay
infusions. The treatment regimen suggested by Gonsette 2003 is
very similar to that reported in Hartung 2002, which represents
the largest trial.
However, it is worthwhile mentioning that another retrospective
open-label study (Debouverie 2004) confirmed the effectiveness of
the treatment regimen recommended in Edan 1997 of sixmonthly
cycles of 20 mg of MX combined with steroids across worsening
RR and SPMS patients. One year after the end of treatment, 44%
of the patients had an EDSS improvement, 39% remained stable
and 17% had deteriorated.
More recent studies are suggesting the use of this drug as a short-
term induction treatment followed bymaintenance immunomod-
ulant treatment in aggressive forms of MS (Edan 2011).
4) Is MX a safe drug?
According to the conclusions of the FDA safety review, “MX was
well tolerated with no deaths, few serious adverse events and few
discontinuations of therapy.No previously unrecognised toxicities
were observed in these studies. No serious cardiotoxicity events
were observed although these studies did not expose patients to
cumulative doses above 100 mg/m2. Cardiotoxicity, neutropenia
and its sequelae, amenorrhoea, which in some cases may be per-
manent, and the potential for late occurring leukaemia are thema-
jor safety concerns associated with MX use (page 42)”. Our meta-
analysis confirmed that there were no deaths or symptomatic car-
diac events among MX-treated patients. Seven out of 111 (6.3%
of the total) MX-treated participants interrupted the treatment for
major side effects, of whom one had asymptomatic LVEF lower
than 50%, one suffered a major depressive episode, one had re-
peated episodes of nausea and vomiting, one had repeated urinary
infections and one had renal failure. Considering the two out of
110 (2% of the total) placebo participants who had treatment
interrupted, one was due to hepatitis and one had a myocardial
infarction.
Thirty-five per cent of female MX-treated participants developed
amenorrhoea, and almost 15% or 12% ??developed a persistent
amenorrhoea which was still present at the end of the study. These
data are similar to those reported by Edan et al, who followed
up a cohort of 800 MX-treated MS participants and found that
6.7% of women younger than 35 years who received MX at a
cumulative dose of 79 mg/m2 developed secondary amenorrhoea
(Edan 2001 b). In these cases, a hormonal substitution therapy
should be started at the onset of amenorrhoea. As a consequence,
patients, especially if of child-bearing age, should be advised of
this potential side effect and also on the potential but not fully
established teratogenic effects of the drug.
Nausea and vomiting, alopecia and urinary tract infections were
more frequent among MX-treated versus placebo-treated par-
ticipants. There are reports of therapy-related acute leukaemia
(TRAL) in MX-treated MS patients, possibly due to a real in-
crement in frequency or to improved surveillance. In contrast to
leukaemias associated with alkylating substances such as cyclo-
phosphamide, MX-related acute leukaemias are characterized by
a short latency, acute onset and cytogenetic changes similar to de
novo leukaemias, such as translocations 11q23, 21q22 or inver-
sion of chromosome 16.Most importantly, they usually respond
to therapy (Quesnel 1993). In June 2004, a total of nine MX-
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treated MS patients, four of whom were single case reports, devel-
oped TRAL (Brassat 2002; Cattaneo 2003; Delisse 2004; Ghalie
2002a; Goodkin 2003; Heesen 2003; Radu 2002; Voltz 2004).
As schematically reported by Voltz (Voltz 2004; page 473, Table
1), the onset of leukaemia ranged from three months after the
end of MX treatment (Goodkin 2003) to five years (Vicari 1998)
across MX-treated MS patients who developed leukaemia, but it
mostly occurred within two years following the cessation of treat-
ment. The cumulative dose of MX treatment before the onset of
leukaemia ranged from 48 mg/m2 to 120 mg/m2. All of the cases
underwent chemotherapy, which was successful in seven out of
nine patients but two patients died. There is a recent report of a
case of acute promyelocytic leukaemia in a patient who received
only 15 mg of MX; however, this patient was affected by breast
cancer and, before receiving MX, she had also been treated with
radiotherapy (Mistry 2005). A meta-analysis tried to measure the
incidence of leukaemia among a cohort of 1378 MX-treated MS
participants from three different trials (Ghalie 2002a): the MIMS
study (Hartung 2002), a French retrospective study (Edan 2001),
and a German retrospective study (Mauch 1999). An incidence
proportion of 0.15% was found after a mean follow-up of 36
months in 1378 patients. This is higher than the proportion of de
novo leukaemias in healthy patients, which typically ranges from
0.001% at 20 years of age to 0.03% at 70 years of age, but lower
than that among patients who underwent combined chemother-
apy, including MX, for whom the leukaemia incidence proportion
ranges from 2% to 12% (Felix 1998). A similar cumulative inci-
dence, 0.21%, was reported by Voltz (Voltz 2004) by pooling the
different cases of leukaemia reported in the literature. A registry
to evaluate the long-term safety profile of MX has been developed
(Goodkin 2001). In the following years, many case series and case
reports have identified 56 to 57 cases of TRAL in MX-treated pa-
tients (for a summary, see table 2 inMarriott 2010), increasing the
incidence of TRAL in MS patients to 33/4076, corresponding to
an incidence of 0.81% and a number needed to harm (NNH) for
TRAL development of 123. Most of these cases occurred within
a few years of MX treatment. A recent multicentre retrospective
cohort study on 3220 MS patients from 40 Italian MS Centers
(Martinelli 2011) with a mean follow-up of 49 months revealed
30 cases of acute myelocytic leukaemia (AML), leading to a very
similar incidence rate of 0.93% (95% CI 0.60% to -1.26%) and a
mortality rate associated with AML of 37%. The median interval
from drug start to AML diagnosis was 33 months, ranging from
13 to 84 months. A dose-dependent relationship was revealed by
this study, corresponding to a 3% increase in the risk of AML for
every one unit increase in MX cumulative dose. According to this
analysis, a cumulative dose between 30 and 60 mg/m2 of body
surface was suggested.
Given this evidence, it is particularly important to carefully check
leukocytes blood levels before any additional MX cycle. A useful
therapeutic scheme is reported in Table 2, where the dosage of
the following MX cycle needs to be adjusted according to the
haematological profile. Moreover, MX-treated patients should be
followed up with complete blood cell counts; the optimal timing
of such monitoring being unclear (Marriott 2010).
Cardiotoxicity is the major limiting factor in the long-term ad-
ministration of MX and sets the maximum cumulative dose at a
total of 140 mg/m2 body surface. MX cardiotoxicity appears to be
due to the generation of free radicals by the drug which, accord-
ing to human autopsy tissue concentration measures, are stored
in elevated concentrations in the heart. The heart represents the
third highest storage deposit of MX after the thyroid and liver
(Stewart 1986). Benjamin 1985 examined endomyocardial biopsy
specimens from 37MX-treated patients, of whom six were treated
with more than 100 mg/m2. Three of them had normal biopsies
while the remaining 34 had histological changes resembling those
caused by anthracyclines, namely a dilatation of the sarcoplasmic
reticulum and myofibrillar dropout. This was, however, defined
as minor and was not expected to be of clinical significance in
the absence of other cardiac abnormalities. The potential risk of
cardiotoxicity could be increased by the fact that a significant pro-
portion of MS patients tend to have impaired cardiac function.
Using radionuclide angiocardiography, Olindo 2002 found in a
cohort of 40MS patients that 25% of them had abnormal LVEFs.
A review (Ghalie 2002b) explored the occurrence of cardiotoxicity
in 1378 MS patients enrolled in three different studies and who
received a mean cumulative dose of MX of 60.5 mg/m2 and were
followed-up for a mean of 30 months. Two cases of congestive
heart failure (CHF) were reported, one had received a dose of
MX higher than 140 mg/m2, leading to an incidence lower than
0.2%. Moreover, a 2.18% (95% CI 1.28 to 3.47) incidence of
an LVEF decrease to below 50% was found among MX-treated
patients. The probability of the event was weakly associated with
the total cumulative dosage received (5% in patients treated with
a total cumulative dosage of MX greater than 100 mg/m2 versus
1.8% in patients treated with a total cumulative dosage lower than
100 mg/m2), which suggests the importance of treating patients
with lower dosages than 100 mg/m2 as well as monitoring them.
This was previously described by De Castro 1995, who found
that a total dose of MX of 96 mg/m2 was not associated with
any cardiac toxicity in MS patients. A recent paper reported a
significant decline of LVEF among 5/28 (17.8%)MSpatients after
three doses of MX and underpins the importance of monitoring
these patients carefully (Avasarala 2003).
More recent studies have reported the occurrence of cardiotoxicity
in MX-treated patients (for a summary, see table 1 in Marriott
2010) leading to an incidence rate of 12% (83/716) for decreased
LVEF and of 0.4% (3/716) for congestive heart failure (CHF),
corresponding to an NNH of 8 and 250 respectively. A phase IV
clinical study of MX to assess its long-term safety and tolerability
reported a 2% CHF occurrence in January 2008 (Rivera 2008).
A registry has been established (Goodkin 2001) to evaluate MX
long-term cardiotoxicity.
From a practical point of view, cardiotoxicity can be reduced by
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performing an electrocardiogram and echocardiography (echocar-
diogram, multi-gated cardiac scan (MUGA), MRI etc.) in all pa-
tients before initiation of therapy, and by performing an echocar-
diography every year during therapy and yearly after cessation of
therapy (FDA 1999; FDA 2012; FDA 2012b). However, the re-
cent report of the occurrence of delayed cardiotoxicity 24, 39 and
80months after the last dose in threeMSpatients treatedwith a cu-
mulative dose of 144 mg/m2 of MX underpins the need to extend
the long-term surveillance of MX cardiotoxicity (Goffette 2005).
Moreover, an echocardiography should be performed whenever
patients develop symptoms of CHF. Treatment should never be
started if the baseline LVEF is below 50% and should be stopped
if the LVEF decreases by more than 10% from the baseline value
or to below 50% during therapy. The total cumulative dosage of
MX should not be higher than 100 mg/m2. It seems important
to also reduce the rate of infusion over 30 minutes in order to
decrease peak drug levels, which could be associated with a higher
risk of cardiotoxicity (Gonsette 2003). A study (Bernitsas 2006)
tested the potential reduction of MX-related cardiotoxicity by the
concomitant administration of dexrazoxane (DRX). This drug
protects the heart by chelating iron from complexes of iron and
anthracyclines and reducing free radical formation (Mikol 2001;
Weiss 1999). It could be administered to patients at the beginning
ofMX therapy.MS patients treated with (n = 28) or without DRX
in conjunction with MX had significant LEVF reduction at one
year, however the reduction was proportionally different (-3.8%
compared to -8.6%, P < 0.001) (Bernitsas 2006).
We are aware of the development of a new analogue ofMX, named
BBR2778 or pixantrone (PIX), which belongs to a novel class of
anthracene-9,10 diones characterized by the introduction of a ni-
trogen functionality in the nucleus and by the lack of two hydroxy
groups. This could be an effective treatment for MS and not car-
diotoxic (Krapcho 1994). According to experimental studies on
EAE animal models, PIX was found to reduce the severity of the
disease and, unlike MX, not to be cardiotoxic (Cavaletti 2004).
Moreover, the weak cardiotoxicity of PIX has been confirmed in
three phase II trials in PIX-treated patients affected with different
tumours. We do not have more recent information on this drug.
Overall completeness and applicability of
evidence
Despite the several sources of potential heterogeneity across the
included trials, in terms of outcomemeasures definition (disability
progression), inclusion criteria, and treatment dosage and regimen,
they support and confirm the short-term efficacy and safety of the
drug.
Quality of the evidence
Three trials involving 221 participants provided moderate evi-
dence on the efficacy and short-term safety of the drug but no
information on longer follow-up. Overall, their methodological
quality was considered to be good with regard to the most com-
mon and relevant biases, even if type of issues found was hetero-
geneous
Potential biases in the review process
A careful and comprehensive search was performed to limit bias
in the review process, which was not language restricted and was
expanded to other sources, such as contacts with authors of the
primary articles. The evaluation of eligibility of studies for inclu-
sion in this review and the extraction of data were performed in-
dependently in order to minimise the additional potential biases
to those already reported in the risk of bias table (Characteristics
of included studies). Any disagreement was resolved by discussion
between authors. Only three randomised, double-blinded con-
trolled trials comparing MX administration versus placebo have
been retrieved from the literature.
Agreements and disagreements with other
studies or reviews
Our review is in substantial agreement with the more recent ver-
sion of the report of the Therapeutics and Technology Assessment
Subcommittee of the American Academy of Neurology (Marriott
2010), which supports the efficacy of MX but also strengthens the
long-term risk of cardiotoxicity and TRAL related to this drug,
found in long-term observational studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found amoderate effect ofMX treatment in reducing disability
progression and the frequency of exacerbations in patients affected
by worsening RR, PR and SPMS in the short-term follow-up (two
years). Information on the frequency and severity of side effects
and adverse events is limited to a follow-up period of two years,
while the efficacy and safety ofMX in longer follow-up is described
in the framework of a few observational studies.
Given the partial efficacy of MX and the increased reports in the
literature of cardiotoxicity (~12% of risk of systolic disfunction)
and therapy-related leukemias events (0.8%) in MX-treated pa-
tients, MX should be limited to treating patients with worsening
RR and SP MS with evidence of persistent inflammatory activity,
after a careful assessment of the individual patients’ risk and benefit
profiles, which should also consider the availability of alternative
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therapies with less severe adverse events. Moreover, MX-treated
patients need to be followed-up after the end of treatment to con-
trol the risk of these serious adverse events. Also, the selection of
which drug to switch to needs to be considered carefully in light of
the risk of tumour or progressive multifocal leucoencephalopathy
(PML) occurrence.
Given the evidence of a dose-effect relationship for adverse events,
a more favourable risk-benefit profile of MX might be considered
when the drug is used for a short-term induction treatment fol-
lowed by a maintenance immunomodulating treatment.
Implications for research
There is a need to provide efficacy and safety data (namely, reg-
istries to carefully follow the risk of cardiotoxicity and TRAL
among MX-treated patients) for longer follow-up periods than
those reported in clinical trials. Other questions still open are as
follows.
1)What is the optimal treatment regimen in terms of total dosage,
frequency of administration and treatment duration?
2) Which type of MS patient benefits most from the therapy?
3) Should patients receive additional treatment during the MX
cycle, namely a combined therapeutical strategy?
4) What is the efficacy of the drug considering paraclinical mea-
sures of disease burden and evolution?
A large multicentre phase III trial of mitoxantrone in SP and wors-
ening RRMS is highly warranted to replicate data obtained in the
largest MIMS study (Hartung 2002) with similar dosage and fre-
quency of administration.
Moreover, a special effort should be made to implement potential
cardioprotective agents in order to reduce the risk of MX-related
cardiotoxicity and to allow the duration of MX treatment to be
extended. A phase I trial with PIX and one with DRX on rapidly
progressing MS are highly warranted (Gonsette 2004).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Edan 1997
Methods Randomised controlled trial.
Central randomisation.
Intention to treat used, even if not specified in the paper.
Double blinded: but in discussion it is specified that blinding of patients is difficult for
MX side effects and blinding of the physicians is difficult for the decrease in white cell
count.
Treatment period: 6 months.
No follow-up.
Withdrawn criteria: not pre-specified.
Withdrawals: 5 ”due to pronounced clinical worsening“ (all in MP group).
Lost to follow-up: no follow-up.
Participants 42 patients: 21 MX + MetylP; 21 MetylP.
6 Centres.
Sex: both.
Included: CDMS with a RR (at least 2 exacerbations with sequelae within the previous
12 months) or SP course (progression of 2 points on EDSS scale within the previous
12 months); disease duration < 10 years; age between 18 and 65 years; EDSS ≤ 6.0; at
least 1 MRI enhancing lesion during the baseline period (defined as the period between
2 months before the baseline visit and the baseline visit, during which all the patients
received 1 g MetylP once a month).
Excluded: coexistence of other severe illnesses; pregnancy; immunosuppressant drugs
use 3 months before entry; corticotropin or corticosteroids use 1 month before entry.
Baseline characteristics:
Sex: MX+MetylP 71,4% female; MetylP 52,3 % female.
Mean Age (SD): MX+MetylP 31,4 years (8,3); MetylP 32,2 years (8,1).
Mean EDSS (SD): MX+MetylP 4.5 (1.6), MetylP 4.6 (1.7).
Mean disease duration (SD): MX+MetylP 6,9 years (3,6), MetylP 5,7 years (4).
Age at onset of MS (SD): MX+MetylP 25,1 (7); MetylP 26,6 (6,5).
Number of relapses 1 year before the inclusion (SD): MX+MetylP 3,1 (1,8); MetylP 2,
4 (1,7).
Course of disease: MX+MetylP (80,9% RR; 19,1% SP); MetylP (71,4% RR; 28,6% SP)
Interventions Rx: 20 mg MX + 1 g. MetylP i.v.
Placebo: 1 g. MetylP i.v.
(Between Month -2 and baseline: MetylP 1 g. i.v. for either groups).
Administration: once a month.
Total dosage: MX 120 mg over 6 months.
Outcomes Primary outcomes:
(1) Proportion of patients who develop new T1 enhancing lesions on serial gadolinium
MRI scans during trial.
Secondary outcomes:
(1) Mean number of new enhanced lesions per month per patient; (2) Mean number of
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Edan 1997 (Continued)
new T2 lesions between baseline and end of trial; (3) Mean EDSS difference between
baseline and end of trial; (4) Mean number of exacerbations between baseline and end
of trial
Notes Definitions: Progression of disability: Confirmed increase of 1.0 EDSS point if baseline
EDSS <= 5,5, or of a 0.5 EDSS point if baseline EDSS >= 6.0, between month 0 and the
end of the study (measured for two months running at the end of the study). Relapse:
occurrence of symptoms of neurological disfunction lasting more than 48 hours and
preceded by stability or improvement for at least 30 days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Low risk ”The allocation of the treatment at month
0 was done after inclusion by a central ran-
domisation service by fax.“ Page 113
Blinding (performance bias and detection
bias)
For investigator e patients
High risk ”In the present study, although the allo-
cation of treatment was performed using
an unbiased randomisation service, neither
the patients nor the clinical investigators
were blinded during the study. Blinding of
patients was not possible in this trial, as ob-
vious side effects of mitoxantrone were ex-
perienced in almost all cases. Blinding of
the physician was made difficult by the fall
inwhite cell count that always accompanies
mitoxantrone treatment. Blind clinical ob-
serversmight have been appointed, but this
could not be done for economic reasons.
The clinical efficacy suggested in this study
must therefore be regarded with caution as
it was acquired unblinded.” (Page 116)
Only the two MRI observers were blinded
to patients’ clinical status
Incomplete outcome data (attrition bias)
All outcomes
High risk 5 withdrawals “due to pronounced clinical
worsening” (all in the methylprednisolone
group) were not included in the 6 months
follow-up analysis. Bias is toward a reduced
efficacy of the drug, on the reduction of the
disability progression since all excluded pa-
tients in the control group worsened dur-
ing the study
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Edan 1997 (Continued)
Selective reporting (reporting bias) Low risk Protocol not available. Outcomes were re-
ported completely, even if the total number
of relapses in the two arms was reported,
but not the distribution in patients. More-
over, the two arms were not matched for
baseline number of enhancing lesions
Other bias High risk Sustained disability progression confirmed
every 2 months.
Possibility that part of the benefit reported
in the mitoxantrone group came from
the addition of methylprednisolone to the
treatment regimen
Notes: It’s unclear if this study was spon-
sored.
Hartung 2002
Methods Randomised controlled trial.
Central computer randomisation.
Intention to treat.
Participants 188 patients: 63 MX 12 mg; 66 MX 5 mg; 65 Placebo.
17 centres.
Sex: both.
Included: CDMS with a SP or PR course; duration of disease not specified; progression
of at least 1.0 point on EDSS scale in preceding 18 months of study entry; age between
18 and 65 years; EDSS: between 3.0 and 6.0; WBC> 4.0*10ˆ9/L; platelet count >
100*10ˆ9/L.
Excluded: co-existence of other severe illnesses; pregnancy; immunosuppressant/im-
munomodulant use before study entry; relapses or corticosteroids use in preceding 8
weeks before entry; LVEF < 50%.
Baseline characteristics:
Sex: MX 12: 46,6% female; MX 5: 60,9% female; placebo: 48,4% female.
Mean Age (SD): MX 12 40 years (6.8); MX 5 39.9 ( 8.1); placebo 40 (7.9).
Mean EDSS (SD): MX 12 4.5 (1.1), MX 5 4.6 (1.0), placebo 4.7 (0.9).
Mean disease duration (SD): MX 12 9.6 (6.9), MX 5 9 (6.2), placebo 10.3 (6.9).
Number of relapses 1 year before the inclusion (SD): MX 12 1.3 (1.1), MX 5 1.4 (1.3),
placebo 1.3 (1.1).
Course of disease: MX 12 (SP 53%, PR 47%), MX 5 (SP 42%, PR 58%), placebo (SP
55%, PR 45%)
Interventions Rx: MX 12: 12 mg/m2 body surface i.v. + ondansentron 8 mg per os.
Rx MX 5: 5 mg/m2 body surface i.v. + ondansentron 8 mg per os.
Placebo: placebo solution (15 mg) + 3 mg methylene blue i.v.
+ ondansentron 16 mg per os.
Administration every 3 months over 24 months. Total dosage: MX 12, 8 dosages over
24 months (total: 96 mg/m2 body surface). MX 5: 8 dosages over 24 months (total: 40
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Hartung 2002 (Continued)
mg/m2 body surface).
The RxMX 5: 5 mg/m2 body surface i.v. + ondansentron 8 mg per os arm was excluded
from the analyses
Outcomes Primary outcomes:
1) EDSS difference between final and baseline.
2) Ambulation index (AI) difference between final and baseline.
3) Number of treated relapses.
4) Time to first treated relapse.
5) Proportion of patients with confirmed EDSS progression.
Secondary outcomes:
6) Proportion of patients with deterioration of at least 1.0 EDSS point.
7) Proportion of patients with such EDSS deterioration confirmed after 3 and 6 months.
8) Time to first sustained EDSS deterioration
9) Time to first relapse.
10) Number and annualised rate of relapses.
11) Proportion of patients with no relapses.
12) Number of days of hospitalisation.
13) Use of wheelchair assistance.
14) Quality of life assessed by Stanford Health questionnaire.
15) Number and volume of gadolinium-enhancing lesions.
16) Number and volume of T-1 lesions.
17) Number and volume of T-2 scans.
Notes Definitions:
Progression of disability: 6-months confirmed increase of at least 1.0 EDSS point.
Relapse: occurrence of new symptoms lasting for more than 48 hours with a change in
functional systems of more than 2 points or deterioration of at least 1 point in either
piramidal, brainstem, cerebellar or visual FS
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was done by means of a
computer-generated schedule prepared for
each site with a block size of three, without
stratification.” Page 2019
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding (performance bias and detection
bias)
For investigator e patients
Low risk EDSS assessor was unaware. A separate
treating physician was aware of treatment
assignment. Lesion load was estimated by
means of a scoring system by two experi-
enced readers, masked to treatment assign-
ment (Page 2020).
”This physician was allowed to speak to
patients only as necessary to carry out
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Hartung 2002 (Continued)
the neurological tests. Before patients were
enrolled, assessing physicians completed
a training session to standardise scoring
on the three tests [EDSS,ambulation in-
dex and standardised neurological status
scores]” Page 2019
Incomplete outcome data (attrition bias)
All outcomes
Low risk The authors state that “188 patients were
included in the intention-to-treat analysis
of efficacy at 24 months” (194 at the onset)
. Reasons seemed similar
Selective reporting (reporting bias) Low risk Protocol not available. Outcomes were re-
ported completely.
Other bias Low risk Notes: Wyeth-Lederle Benelux and Ger-
many sponsored this trial and financially
supported independent statistical analysis.
Page 2021
Millefiorini 1997
Methods Randomised controlled trial.
Central randomisation and allocation.
Intention to treat.
Participants 51 patients: 27 MX 8 mg; 24 Placebo.
8 centres.
Sex: both.
Included: CDMS or LSMS with a RR course; disease duration between 1 and 10 years;
at least 2 relapses in the previous 2 years; age between 18 and 45 years; EDSS: between
2.0 and 5.0; MRI criteria not specified.
Excluded: presence of previous cardiovascular disease; pregnancy; immunosuppressant
drugs use 3 months before entry; relapses or corticosteroids use in preceding 3 months
before entry; LVEF< 50%.
Baseline characteristics:
Sex: MX 8 (62.9 % female); placebo (75% female).
Mean Age (SD): MX 8 30.9 years (6.0); placebo 28.7 (6.5).
Mean EDSS (SD): MX 8 3.6 (0.9), placebo 3.5 (1.2).
Mean disease duration (SD): MX 8 5.7 years; placebo 5.0.
Number of relapses 2 years before the inclusion (SD): MX 8 2.8 (1.2), placebo 2.8 (1.
1).
Course of disease: MX 8, RR 100%; placebo, RR 100%.
Interventions Rx: MX 8: 8 mg/m2 body surface i.v.
Placebo: placebo solution i.v.
Administration: every month over 12 months (total dosage: 96 mg/m2 body surface).
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Millefiorini 1997 (Continued)
Outcomes Primary outcomes:
(1) Proportion of patients with confirmed progression (2) Annual mean number of
exacerbations and percentage of exacerbation-free patients;
(3) Change in mean EDSS from baseline to final;
(4) Mean number of new or enlarged T2-lesions performed at baseline, 12-month and
24-month
Notes Definitions:
Progression of disability: 3-months confirmed progression of the disease as measured by
an increase of at least 1.0 point on EDSS scale.
Relapses: appearance of a new symptom or worsening of an old symptom, attributed to
MS, accompanied by a documented new neurological abnormality lasting more than 48
hours and preceded by stability or improvement for at least 30 days.
MRI new lesions: lesions not present in T2 in previous scans.
MRI enlarged lesions: lesions 33% larger in size when compared with previous ones
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “When a patient became eligible, the inves-
tigators notified the relevant centre which
validated the eligibility of the patient and
assigned a randomisation code number.
The subject was then randomly assigned to
a recipient group that received eitherMTX
or a placebo. Patients were randomised to
MTX or placebo using a scheme strati-
fied on age, sex and EDSS which resulted
in eight different age/sex/EDSS strata. Ac-
cording to the study protocol, within each
stratum the allocation of patients to treat-
ment or placebo was balanced by using a
block design of size eight.” Page 154
Allocation concealment (selection bias) Low risk Central allocation and the intravenous bag
and tubing were black to ensure no differ-
ences between the treatment groups. Page
154
Blinding (performance bias and detection
bias)
For investigator e patients
Low risk The neurologist, who evaluated the EDSS
scale, was blinded. “In order to maintain
blindness, the interaction of the EDSS
physicians with the patient was strictly re-
stricted to the neurological examination.
The neurologist was not allowed to talk
with the patient about adverse events, or
any other issue which could potentially dis-
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Millefiorini 1997 (Continued)
close the patient’s treatment.” Page 154
“MRI data were analysed by two blinded
neuroradiologists” Page 155
BUT “It must be emphasized that while
EDSS evaluation was performed by four
blinded neurologists, the assessment of
exacerbations was monitored by treating
physicians not blinded to study treatment
(see Patients andmethods). The unblended
assessment of exacerbations suggests a po-
tential systematic bias concerning treat-
ment efficacy (false positive, type 1 error)
. This type of error, however, is a crucial
element when the EDSS score must be as-
signed, while it seems to be less relevant
in recording objective neurological findings
such as determining that an exacerbation
has taken place.” Page 157
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised patients were included in
the analysis.
For MRI outcome measure, 9 out of 51 pa-
tients did not complete the MRI study for
the following reasons:2 MX and 4 placebo
patients felt the drug was not working, 1
MX patient did not have good compliance
with his neuroradiological centre, 1 MX
and 1 placebo patients withdrew for non-
medical reasons
Selective reporting (reporting bias) Low risk Protocol not available. Outcomes were re-
ported completely, even if “The lack of
a total lesion volume evaluation on T2-
weighted images, which is the most ap-
propriate measurement for long-term stud-
ies, and the use of different MRI imagers,
which might be a significant source of vari-
ation for lesion measurements, appear to
be the major limitations of the present
study and might explain the apparent in-
congruity between clinical and MRI re-
sults.” Page 157-158
Other bias High risk ”The incomplete recruitment generated an
imbalance in term of sex.” Page 155
No adequate AEs monitoring (self-re-
ported).
Notes: It is unclear if this study was spon-
sored.
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CDMS: Clinically-definite multiple sclerosis
EDSS: Expanded Disability Status Scale
LSMS: Laboratory-supported multiple sclerosis
LVEF: Left ventricular ejection fraction
MetylP: Methylprednisolone
MS: Multiple sclerosis






WBC: White blood count
I.V.: Intravenous
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Capra 1993 Open label pilot study
Edan 2001 Observational safety study
Edan 2011 RCT, absence of placebo arm
Gonsette 1990 Open label pilot study
Goodkin 2001 Observational safety study
Hamzehloo 2007 Observational study
Kappos 1990 Open label pilot study
Kornhuber 1992 Open label pilot study
Krapf 1995 Open label pilot study. Only MRI outcome
Mauch 1999 Observational efficacy and safety study
Noseworthy 1993 Open label pilot study
Rees 1998 Open label pilot study
Van de Wyngaert 2001 RCT, mitoxantrone versus methylprednisolone; absence of placebo group
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D A T A A N D A N A L Y S E S
Comparison 1. Mitoxantrone versus placebo: primary outcomes




participants Statistical method Effect size
1 Patients with 6-month confirmed
disability progression at 2 years
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Disability progression 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Worst 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Best 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Likely 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Post-hoc analysis: Patients with
3- or 6-month confirmed
disability progression
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 At 1 year 1 51 Odds Ratio (M-H, Fixed, 95% CI) 0.24 [0.04, 1.33]
2.2 At 2 years 2 179 Odds Ratio (M-H, Fixed, 95% CI) 0.23 [0.09, 0.59]
2.3 At 2 years - Worst Scenario 2 179 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.16, 0.83]
2.4 At 2 years - Best Scenario 2 179 Odds Ratio (M-H, Fixed, 95% CI) 0.21 [0.08, 0.55]
2.5 At 2 years - Likely
Scenario
2 179 Odds Ratio (M-H, Fixed, 95% CI) 0.34 [0.15, 0.78]
3 Patients who withdrew from the
study because of major side
effects of the drug
3 221 Odds Ratio (M-H, Fixed, 95% CI) 2.72 [0.51, 14.54]
Comparison 2. Mitoxantrone versus placebo: secondary outcomes




participants Statistical method Effect size
1 Patients with no relapses at 6
months/1 year
2 Odds Ratio (M-H, Random, 95% CI) Totals not selected
1.1 6 months 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 1 year 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Mean change in disability
(EDSS)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 At 1 year 1 25 Mean Difference (IV, Fixed, 95% CI) -0.35 [-0.86, 0.16]
2.2 At 2 years 2 175 Mean Difference (IV, Fixed, 95% CI) -0.36 [-0.70, -0.02]
3 Patients with no relapses at 2
years
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Patients with no relapses 2 179 Odds Ratio (M-H, Fixed, 95% CI) 2.82 [1.54, 5.19]
3.2 Worst Scenario 2 179 Odds Ratio (M-H, Fixed, 95% CI) 2.68 [1.46, 4.92]
3.3 Best Scenario 2 179 Odds Ratio (M-H, Fixed, 95% CI) 3.27 [1.77, 6.04]
3.4 Likely Scenario 2 179 Odds Ratio (M-H, Fixed, 95% CI) 3.11 [1.68, 5.72]
4 Annualized relapse rate 3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 At 6 months/1 year 3 217 Mean Difference (IV, Fixed, 95% CI) -1.02 [-1.69, -0.35]
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4.2 At 2 years 2 175 Mean Difference (IV, Fixed, 95% CI) -0.85 [-1.47, -0.23]
5 Number of MRI active lesions 3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 At 6 months/1 year 2 62 Mean Difference (IV, Fixed, 95% CI) -0.79 [-1.68, 0.09]
5.2 At 2 years 1 70 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Number of patients with active
lesions
3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 At 6 months/1 year 3 132 Odds Ratio (M-H, Fixed, 95% CI) 0.24 [0.10, 0.57]
6.2 At 2 years 1 68 Odds Ratio (M-H, Fixed, 95% CI) 0.09 [0.00, 1.77]
Comparison 3. Mitoxantrone versus placebo: adverse events




participants Statistical method Effect size
1 Amenorrea 3 199 Odds Ratio (M-H, Fixed, 95% CI) 15.50 [4.15, 57.94]
1.1 Amenorrea (general) 3 117 Odds Ratio (M-H, Fixed, 95% CI) 22.31 [4.03, 123.47]
1.2 Persistent Amenorrea 2 82 Odds Ratio (M-H, Fixed, 95% CI) 8.27 [1.02, 67.18]
2 Nausea/Vomiting 3 219 Odds Ratio (M-H, Fixed, 95% CI) 14.01 [6.36, 30.85]
3 Alopecia 3 219 Odds Ratio (M-H, Fixed, 95% CI) 4.65 [2.37, 9.12]
4 Urinary tract Infections 3 219 Odds Ratio (M-H, Fixed, 95% CI) 3.76 [1.67, 8.46]
5 Respiratory tract infections 3 219 Odds Ratio (M-H, Fixed, 95% CI) 1.34 [0.72, 2.50]
6 Headhache 3 219 Odds Ratio (M-H, Fixed, 95% CI) 1.36 [0.44, 4.24]
Comparison 4. Mitoxantrone versus placebo: abnormal laboratory values




participants Statistical method Effect size
1 Leucopenia 2 168 Odds Ratio (M-H, Fixed, 95% CI) 17.95 [2.35, 137.00]
2 Anemia 2 168 Odds Ratio (M-H, Fixed, 95% CI) 4.51 [0.92, 22.20]
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Analysis 1.1. Comparison 1 Mitoxantrone versus placebo: primary outcomes, Outcome 1 Patients with 6-
month confirmed disability progression at 2 years.
Review: Mitoxantrone for multiple sclerosis
Comparison: 1 Mitoxantrone versus placebo: primary outcomes
Outcome: 1 Patients with 6-month confirmed disability progression at 2 years
Study or subgroup Treatment Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Disability progression
Hartung 2002 4/63 12/65 0.30 [ 0.09, 0.99 ]
2 Worst
Hartung 2002 7/63 12/65 0.55 [ 0.20, 1.51 ]
3 Best
Hartung 2002 4/63 13/65 0.27 [ 0.08, 0.88 ]
4 Likely
Hartung 2002 7/63 13/65 0.50 [ 0.19, 1.35 ]
0.05 0.2 1 5 20
Favours treatment Favours control
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Analysis 1.2. Comparison 1 Mitoxantrone versus placebo: primary outcomes, Outcome 2 Post-hoc analysis:
Patients with 3- or 6-month confirmed disability progression.
Review: Mitoxantrone for multiple sclerosis
Comparison: 1 Mitoxantrone versus placebo: primary outcomes
Outcome: 2 Post-hoc analysis: Patients with 3- or 6-month confirmed disability progression
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 1 year
Millefiorini 1997 2/27 6/24 100.0 % 0.24 [ 0.04, 1.33 ]
Subtotal (95% CI) 27 24 100.0 % 0.24 [ 0.04, 1.33 ]
Total events: 2 (Treatment), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
2 At 2 years
Hartung 2002 4/63 12/65 55.6 % 0.30 [ 0.09, 0.99 ]
Millefiorini 1997 2/27 9/24 44.4 % 0.13 [ 0.03, 0.70 ]
Subtotal (95% CI) 90 89 100.0 % 0.23 [ 0.09, 0.59 ]
Total events: 6 (Treatment), 21 (Control)
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0024)
3 At 2 years - Worst Scenario
Hartung 2002 7/63 12/65 54.3 % 0.55 [ 0.20, 1.51 ]
Millefiorini 1997 2/27 9/24 45.7 % 0.13 [ 0.03, 0.70 ]
Subtotal (95% CI) 90 89 100.0 % 0.36 [ 0.16, 0.83 ]
Total events: 9 (Treatment), 21 (Control)
Heterogeneity: Chi2 = 2.07, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 2.39 (P = 0.017)
4 At 2 years - Best Scenario
Hartung 2002 4/63 13/65 57.6 % 0.27 [ 0.08, 0.88 ]
Millefiorini 1997 2/27 9/24 42.4 % 0.13 [ 0.03, 0.70 ]
Subtotal (95% CI) 90 89 100.0 % 0.21 [ 0.08, 0.55 ]
Total events: 6 (Treatment), 22 (Control)
Heterogeneity: Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 3.17 (P = 0.0015)
5 At 2 years - Likely Scenario
Hartung 2002 7/63 13/65 56.3 % 0.50 [ 0.19, 1.35 ]
Millefiorini 1997 2/27 9/24 43.7 % 0.13 [ 0.03, 0.70 ]
Subtotal (95% CI) 90 89 100.0 % 0.34 [ 0.15, 0.78 ]
Total events: 9 (Treatment), 22 (Control)
Heterogeneity: Chi2 = 1.80, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 2.54 (P = 0.011)
0.05 0.2 1 5 20
Favours treatment Favours control
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Analysis 1.3. Comparison 1 Mitoxantrone versus placebo: primary outcomes, Outcome 3 Patients who
withdrew from the study because of major side effects of the drug.
Review: Mitoxantrone for multiple sclerosis
Comparison: 1 Mitoxantrone versus placebo: primary outcomes
Outcome: 3 Patients who withdrew from the study because of major side effects of the drug
Study or subgroup Treatment Control Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Edan 1997 0/21 0/21 0.0 [ 0.0, 0.0 ]
Millefiorini 1997 0/27 0/24 0.0 [ 0.0, 0.0 ]
Hartung 2002 5/63 2/65 2.72 [ 0.51, 14.54 ]
Total (95% CI) 111 110 2.72 [ 0.51, 14.54 ]
Total events: 5 (Treatment), 2 (Control)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours treatment Favours control
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Analysis 2.1. Comparison 2 Mitoxantrone versus placebo: secondary outcomes, Outcome 1 Patients with
no relapses at 6 months/1 year.
Review: Mitoxantrone for multiple sclerosis
Comparison: 2 Mitoxantrone versus placebo: secondary outcomes
Outcome: 1 Patients with no relapses at 6 months/1 year









Edan 1997 14/21 7/21 4.00 [ 1.11, 14.43 ]
2 1 year
Millefiorini 1997 19/27 6/24 7.13 [ 2.06, 24.61 ]
0.05 0.2 1 5 20
Favours control Favours treatment
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Analysis 2.2. Comparison 2 Mitoxantrone versus placebo: secondary outcomes, Outcome 2 Mean change in
disability (EDSS).
Review: Mitoxantrone for multiple sclerosis
Comparison: 2 Mitoxantrone versus placebo: secondary outcomes
Outcome: 2 Mean change in disability (EDSS)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 1 year
Millefiorini 1997 13 -0.27 (0.7) 12 0.08 (0.6) -0.35 [ -0.86, 0.16 ]
Subtotal (95% CI) 13 12 -0.35 [ -0.86, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
2 At 2 years
Hartung 2002 60 -0.13 (0.9) 64 0.23 (1.01) -0.36 [ -0.70, -0.02 ]
Millefiorini 1997 27 -0.1 (0) 24 0.7 (0) 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 87 88 -0.36 [ -0.70, -0.02 ]
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 2.10 (P = 0.036)
-1 -0.5 0 0.5 1
Favours treatment Favours control
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Analysis 2.3. Comparison 2 Mitoxantrone versus placebo: secondary outcomes, Outcome 3 Patients with
no relapses at 2 years.
Review: Mitoxantrone for multiple sclerosis
Comparison: 2 Mitoxantrone versus placebo: secondary outcomes
Outcome: 3 Patients with no relapses at 2 years
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Patients with no relapses
Hartung 2002 34/63 23/65 84.2 % 2.14 [ 1.05, 4.35 ]
Millefiorini 1997 17/27 5/24 15.8 % 6.46 [ 1.84, 22.71 ]
Subtotal (95% CI) 90 89 100.0 % 2.82 [ 1.54, 5.19 ]
Total events: 51 (Treatment), 28 (Control)
Heterogeneity: Chi2 = 2.25, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 3.34 (P = 0.00083)
2 Worst Scenario
Hartung 2002 34/63 24/65 84.7 % 2.00 [ 0.99, 4.06 ]
Millefiorini 1997 17/27 5/24 15.3 % 6.46 [ 1.84, 22.71 ]
Subtotal (95% CI) 90 89 100.0 % 2.68 [ 1.46, 4.92 ]
Total events: 51 (Treatment), 29 (Control)
Heterogeneity: Chi2 = 2.53, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 3.19 (P = 0.0014)
3 Best Scenario
Hartung 2002 37/63 23/65 82.7 % 2.60 [ 1.27, 5.31 ]
Millefiorini 1997 17/27 5/24 17.3 % 6.46 [ 1.84, 22.71 ]
Subtotal (95% CI) 90 89 100.0 % 3.27 [ 1.77, 6.04 ]
Total events: 54 (Treatment), 28 (Control)
Heterogeneity: Chi2 = 1.52, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 3.78 (P = 0.00016)
4 Likely Scenario
Hartung 2002 37/63 24/65 83.3 % 2.43 [ 1.19, 4.95 ]
Millefiorini 1997 17/27 5/24 16.7 % 6.46 [ 1.84, 22.71 ]
Subtotal (95% CI) 90 89 100.0 % 3.11 [ 1.68, 5.72 ]
Total events: 54 (Treatment), 29 (Control)
Heterogeneity: Chi2 = 1.76, df = 1 (P = 0.18); I2 =43%
Test for overall effect: Z = 3.63 (P = 0.00028)
0.05 0.2 1 5 20
Favours control Favours treatment
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Analysis 2.4. Comparison 2 Mitoxantrone versus placebo: secondary outcomes, Outcome 4 Annualized
relapse rate.
Review: Mitoxantrone for multiple sclerosis
Comparison: 2 Mitoxantrone versus placebo: secondary outcomes
Outcome: 4 Annualized relapse rate





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 6 months/1 year
Edan 1997 21 0.7 (0) 21 3 (0) 0.0 [ 0.0, 0.0 ]
Hartung 2002 60 0.42 (0) 64 1.15 (0) 0.0 [ 0.0, 0.0 ]
Millefiorini 1997 27 0.52 (1.1) 24 1.54 (1.3) -1.02 [ -1.69, -0.35 ]
Subtotal (95% CI) 108 109 -1.02 [ -1.69, -0.35 ]
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 3.00 (P = 0.0027)
2 At 2 years
Hartung 2002 60 0.35 (0) 64 1.02 (0) 0.0 [ 0.0, 0.0 ]
Millefiorini 1997 27 0.45 (1.05) 24 1.3 (1.2) -0.85 [ -1.47, -0.23 ]
Subtotal (95% CI) 87 88 -0.85 [ -1.47, -0.23 ]
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 2.68 (P = 0.0074)
-2 -1 0 1 2
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Analysis 2.5. Comparison 2 Mitoxantrone versus placebo: secondary outcomes, Outcome 5 Number of MRI
active lesions.
Review: Mitoxantrone for multiple sclerosis
Comparison: 2 Mitoxantrone versus placebo: secondary outcomes
Outcome: 5 Number of MRI active lesions





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 6 months/1 year
Edan 1997 21 1.4 (5.7) 16 3.1 (3.2) -1.70 [ -4.60, 1.20 ]
Millefiorini 1997 (1) 13 0.46 (0.7) 12 1.16 (1.5) -0.70 [ -1.63, 0.23 ]
Subtotal (95% CI) 34 28 -0.79 [ -1.68, 0.09 ]
Heterogeneity: Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.079)
2 At 2 years
Hartung 2002 (2) 34 0.03 (0) 36 0.26 (0) 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 34 36 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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(1) Data were retrieved from contact with study authors
(2) Data were retrieved from contact with study authors
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Analysis 2.6. Comparison 2 Mitoxantrone versus placebo: secondary outcomes, Outcome 6 Number of
patients with active lesions.
Review: Mitoxantrone for multiple sclerosis
Comparison: 2 Mitoxantrone versus placebo: secondary outcomes
Outcome: 6 Number of patients with active lesions
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 6 months/1 year
Edan 1997 2/21 11/16 50.6 % 0.05 [ 0.01, 0.29 ]
Hartung 2002 (1) 4/34 7/36 26.9 % 0.55 [ 0.15, 2.09 ]
Millefiorini 1997 (2) 4/13 7/12 22.6 % 0.32 [ 0.06, 1.64 ]
Subtotal (95% CI) 68 64 100.0 % 0.24 [ 0.10, 0.57 ]
Total events: 10 (Treatment), 25 (Control)
Heterogeneity: Chi2 = 4.69, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 3.25 (P = 0.0012)
2 At 2 years
Hartung 2002 (3) 0/31 5/37 100.0 % 0.09 [ 0.00, 1.77 ]
Subtotal (95% CI) 31 37 100.0 % 0.09 [ 0.00, 1.77 ]
Total events: 0 (Treatment), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Chi2 = 0.38, df = 1 (P = 0.54), I2 =0.0%
0.005 0.1 1 10 200
Favours treatment Favours control
(1) Data were retrieved from contact with study authors
(2) Data were retrieved from contact with study authors
(3) Data were retrieved from contact with study authors
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Analysis 3.1. Comparison 3 Mitoxantrone versus placebo: adverse events, Outcome 1 Amenorrea.
Review: Mitoxantrone for multiple sclerosis
Comparison: 3 Mitoxantrone versus placebo: adverse events
Outcome: 1 Amenorrea
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Amenorrea (general)
Edan 1997 8/15 0/11 14.9 % 26.07 [ 1.30, 521.91 ]
Hartung 2002 7/25 0/31 17.8 % 25.54 [ 1.38, 473.42 ]
Millefiorini 1997 5/17 0/18 18.8 % 16.28 [ 0.82, 321.37 ]
Subtotal (95% CI) 57 60 51.5 % 22.31 [ 4.03, 123.47 ]
Total events: 20 (Treatment), 0 (Control)
Heterogeneity: Chi2 = 0.06, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 3.56 (P = 0.00038)
2 Persistent Amenorrea
Edan 1997 1/15 0/11 28.8 % 2.38 [ 0.09, 64.05 ]
Hartung 2002 5/25 0/31 19.7 % 16.90 [ 0.89, 322.29 ]
Subtotal (95% CI) 40 42 48.5 % 8.27 [ 1.02, 67.18 ]
Total events: 6 (Treatment), 0 (Control)
Heterogeneity: Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.98 (P = 0.048)
Total (95% CI) 97 102 100.0 % 15.50 [ 4.15, 57.94 ]
Total events: 26 (Treatment), 0 (Control)
Heterogeneity: Chi2 = 1.48, df = 4 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 4.07 (P = 0.000046)
Test for subgroup differences: Chi2 = 0.52, df = 1 (P = 0.47), I2 =0.0%
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Analysis 3.2. Comparison 3 Mitoxantrone versus placebo: adverse events, Outcome 2 Nausea/Vomiting.
Review: Mitoxantrone for multiple sclerosis
Comparison: 3 Mitoxantrone versus placebo: adverse events
Outcome: 2 Nausea/Vomiting
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Edan 1997 6/21 0/21 9.3 % 18.03 [ 0.94, 344.40 ]
Hartung 2002 47/62 13/64 81.5 % 12.29 [ 5.30, 28.53 ]
Millefiorini 1997 9/27 0/24 9.2 % 25.16 [ 1.37, 460.60 ]
Total (95% CI) 110 109 100.0 % 14.01 [ 6.36, 30.85 ]
Total events: 62 (Treatment), 13 (Control)
Heterogeneity: Chi2 = 0.28, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 6.55 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 3.3. Comparison 3 Mitoxantrone versus placebo: adverse events, Outcome 3 Alopecia.
Review: Mitoxantrone for multiple sclerosis
Comparison: 3 Mitoxantrone versus placebo: adverse events
Outcome: 3 Alopecia
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Edan 1997 7/21 0/21 3.9 % 22.24 [ 1.18, 420.36 ]
Hartung 2002 38/62 20/64 91.0 % 3.48 [ 1.67, 7.27 ]
Millefiorini 1997 5/27 0/24 5.1 % 11.98 [ 0.63, 229.09 ]
Total (95% CI) 110 109 100.0 % 4.65 [ 2.37, 9.12 ]
Total events: 50 (Treatment), 20 (Control)
Heterogeneity: Chi2 = 2.08, df = 2 (P = 0.35); I2 =4%
Test for overall effect: Z = 4.47 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Mitoxantrone versus placebo: adverse events, Outcome 4 Urinary tract
Infections.
Review: Mitoxantrone for multiple sclerosis
Comparison: 3 Mitoxantrone versus placebo: adverse events
Outcome: 4 Urinary tract Infections
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Edan 1997 4/21 1/21 12.3 % 4.71 [ 0.48, 46.22 ]
Hartung 2002 20/62 8/64 80.7 % 3.33 [ 1.34, 8.30 ]
Millefiorini 1997 3/27 0/24 7.0 % 7.00 [ 0.34, 142.81 ]
Total (95% CI) 110 109 100.0 % 3.76 [ 1.67, 8.46 ]
Total events: 27 (Treatment), 9 (Control)
Heterogeneity: Chi2 = 0.27, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 3.20 (P = 0.0014)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Mitoxantrone versus placebo: adverse events, Outcome 5 Respiratory tract
infections.
Review: Mitoxantrone for multiple sclerosis
Comparison: 3 Mitoxantrone versus placebo: adverse events
Outcome: 5 Respiratory tract infections
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Edan 1997 5/21 2/21 8.9 % 2.97 [ 0.51, 17.42 ]
Hartung 2002 33/62 33/64 88.3 % 1.07 [ 0.53, 2.15 ]
Millefiorini 1997 2/27 0/24 2.8 % 4.80 [ 0.22, 105.22 ]
Total (95% CI) 110 109 100.0 % 1.34 [ 0.72, 2.50 ]
Total events: 40 (Treatment), 35 (Control)
Heterogeneity: Chi2 = 1.84, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Mitoxantrone versus placebo: adverse events, Outcome 6 Headhache.
Review: Mitoxantrone for multiple sclerosis
Comparison: 3 Mitoxantrone versus placebo: adverse events
Outcome: 6 Headhache
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Edan 1997 0/21 1/21 28.4 % 0.32 [ 0.01, 8.26 ]
Hartung 2002 4/62 3/64 53.4 % 1.40 [ 0.30, 6.54 ]
Millefiorini 1997 3/27 1/24 18.2 % 2.88 [ 0.28, 29.68 ]
Total (95% CI) 110 109 100.0 % 1.36 [ 0.44, 4.24 ]
Total events: 7 (Treatment), 5 (Control)
Heterogeneity: Chi2 = 1.16, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Mitoxantrone versus placebo: abnormal laboratory values, Outcome 1
Leucopenia.
Review: Mitoxantrone for multiple sclerosis
Comparison: 4 Mitoxantrone versus placebo: abnormal laboratory values
Outcome: 1 Leucopenia
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Edan 1997 2/21 0/21 52.9 % 5.51 [ 0.25, 122.08 ]
Hartung 2002 12/62 0/64 47.1 % 31.93 [ 1.85, 552.34 ]
Total (95% CI) 83 85 100.0 % 17.95 [ 2.35, 137.00 ]
Total events: 14 (Treatment), 0 (Control)
Heterogeneity: Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.79 (P = 0.0053)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Mitoxantrone versus placebo: abnormal laboratory values, Outcome 2 Anemia.
Review: Mitoxantrone for multiple sclerosis
Comparison: 4 Mitoxantrone versus placebo: abnormal laboratory values
Outcome: 2 Anemia
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Edan 1997 4/21 1/21 46.8 % 4.71 [ 0.48, 46.22 ]
Hartung 2002 4/62 1/64 53.2 % 4.34 [ 0.47, 40.01 ]
Total (95% CI) 83 85 100.0 % 4.51 [ 0.92, 22.20 ]
Total events: 8 (Treatment), 2 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.85 (P = 0.064)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Number and reasons of withdrawn or loss to follow-up in included studies
Studies Withdrawn













0 0 0 Placebo: 5 0 Placebo: 5
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Placebo: 2 Placebo: 18
Table 2. Mitoxantrone dosage adjustment
Dose to be given 100% 90% 75% Stop
If: Leucocytes (x1000/
ml)
>= 4 3-3.99 2-2.99 < 2
If: Granulocytes (x1000/
ml)
>= 2 1.5-1.99 1-1.49 < 1
If: Platelets (x1000/ml) >= 100 75-99 50-74 < 50
A P P E N D I C E S
Appendix 1. Keywords
{novantrone} OR {novantron} OR {pralifan} OR {mitoxantrone}
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WH A T ’ S N E W
Last assessed as up-to-date: 30 May 2013.
Date Event Description
30 May 2013 Review declared as stable From 2005, no new RCTs matched our inclusion criteria. To our knowledge, no
more study versus placebo started or are ongoing
23 May 2013 New search has been performed Search was re-run.
H I S T O R Y
Protocol first published: Issue 2, 2000
Review first published: Issue 4, 2005
Date Event Description
30 August 2012 New citation required but conclusions have not
changed
No new trials have been identified.
Risk of bias tables and a secondary outcome have been
added.
A previous included trial was excluded from the update
of this review because it did not fulfil our inclusion
criteria
The terms of comparison have been better defined.
The text has been amended throughout.
18 June 2012 New search has been performed Search was re-run.
12 November 2008 Amended Abstract, declaration of Interest and Next stage ex-
pected.
25 August 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
F Martinelli Boneschi and M Rovaris ideated the project.
M Rovaris, F Martinelli Boneschi and R Capra selected and reviewed the articles.
F Martinelli Boneschi wrote the final text.
M Rovaris, R Capra and G Comi supervised the review.
F Martinelli Boneschi and L Vacchi managed the review update: they assessed the relevance and quality of the articles found; abstracted
data; re-checked the analysis, the results and conclusion.
F Martinelli Boneschi, L Vacchi, M Rovaris, R Capra and G Comi reviewed the text.
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D E C L A R A T I O N S O F I N T E R E S T
The review was assembled, analysed and reported independently of any pharmaceutical company.
Dr Martinelli Boneschi received personal compensations for activities from BiogenIdec Italy, Dompè-Biogen Italy, Merck-Serono.
Dr Rovaris has received personal compensations for activities with: TEVA Pharmaceutical Industries, Novartis Pharma, Sanofi-Aventis
Italy and Biogenidec Italy.
Dr Capra received consulting fees fromNovartis,Merck Serono, BiogenIdec and lecture fees fromBayer, BiogenIdec, Dompé, Genzyme
and Sanofi-Aventis
Prof Comi has received grants and honoraria for his consulting activity from Teva, Merck-Serono, Biogenidec, Sanofi-Aventis Italia
and Schering.
Dr Vacchi has no conflict of interest.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Review team changed between protocol and review.
Doctor Vacchi joined the team for the 2013 update.
In the 2013 update (Martinelli Boneschi 2013), no new RCTs were included, but the exclusion of one trial previously included in
this review (Van de Wyngaert 2001) caused a partial revision of analyses and discussion. The review team decided to exclude this trial
because it didn’t entirely meet the inclusion criteria (absence of a clean placebo group, treated with steroids).
The terms of comparison have been better defined (MX versus placebo or MX plus steroids treatment versus placebo plus steroids).
A secondary outcome (’Abnormal laboratory values’) has been added.
Further, due to the new Cochrane rules, an exhaustive description of risk of bias has been added.
Since the last research strategies of the literature did not reveal any new references of that could meet the inclusion criteria, the current
review can be considered as final.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Disease Progression; Immunosuppressive Agents [adverse effects; ∗therapeutic use]; Mitoxantrone [adverse effects; ∗therapeutic use];
Multiple Sclerosis [drug therapy]; Multiple Sclerosis, Chronic Progressive [∗drug therapy]; Multiple Sclerosis, Relapsing-Remitting
[∗drug therapy]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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